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1 
EXPLANATION OF DISSERTATION FORMAT 
This dissertation has been prepared in the alternative format in accor­
dance with the specifications described in Iowa State University Graduate 
College Thesis Manual (1990). Use of the alternative format allows prepara­
tion of independent sections which are suitable for submission to a scientific 
journal for publication. 
Following the GENERAL INTRODUCTION on page 2, a LITERATURE 
REVIEW of topics pertinent to the dissertation research is presented. Fol­
lowing the LITERATURE REVIEW are two complete papers (SECTIONS I 
and II) and each paper includes abstract, introduction, materials and meth­
ods, results, discussion, and references. A GENERAL SUMMARY follows 
the papers and is intended to cite briefly the major conclusions and to make 
suggestions for additional research. Finally, a section named ADDITIONAL 
REFERENCES provides references cited in LITERATURE REVIEW. 
2 
GENERAL INTRODUCTION 
The corpus luteum is a small gland that develops rapidly from the ovu­
lated follicle and performs a vital function in the reproductive process, namely 
the secretion of progesterone, which is indispensible for the establishment and 
maintenance of pregnancy that lasts 113-115 day in the pig. Corpora lutea 
of this species also produce relaxin, a peptide hormone of about 6,000 daltons 
that plays a critical role in suppressing uterine motility during pregnancy and 
in remodeling connective tissue in preparation for imminent parturition. 
After mating, peripheral blood progesterone increases to a peak (=35 
ng/ml) and remains elevated (=18 ng/ml) for the major part of gestation, then 
it decreases, a few days before parturition to a low level (< 3 ng/ml). Relaxin 
in peripheral blood remains low (%2 ng/ml) before day 100 of the pregnancy 
and it increases gradually thereafter, reaching a peak of 50-250 ng/ml about 
one day before parturition, then it declines at birth and remains low (< 1 
ng/ml) throughout lactation. 
Hysterectomy of nongravid pigs during the early part of the estrous cycle 
sustains luteal function until about day 150 and relaxin and progesterone lev­
els in peripheral blood show the same secretion patterns as those of the preg­
nant pigs at comparable stages. The mechanisms that control such a precisely 
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timed peak relaxin release and coincident decrease in progesterone secretion 
in both pregnant and hysterectomized pigs are poorly understood. The objec­
tives of present studies were to: 1) investigate the role of progesterone and its 
receptor in the regulation of luteal function and prolactin (PRL) secretion by 
using progesterone receptor antagonist, RU 486; and 2) determine the effects 
of relaxin and RU 486, when applied intracerebroventricularly, on pituitary 
hormone secretion and luteal function. 
4 
LITERATURE REVIEW 
Relàxin 
Relaxin was discovered by F. L. Hisaw in 1926 when he found that in­
jection of serum from pregnant rabbits or guinea pigs into virgin guinea pigs 
shortly after estrus was able to cause a relaxation of the interpubic ligament. 
The presence of relaxin has been reported in a variety of animals. Although 
it has been found in the testes of roosters (Steinetz et al., 1959) and in human 
seminal plasma (Loumaye et al., 1980), relaxin is found primarily in the fe­
male reproductive tract during pregnancy (Schwabe et al., 1978). The corpus 
luteum of pregnancy is recognized as the primary source of relaxin in the sow 
(Fevold et al., 1930; Belt et al., 1971), the cow (Fields et al., 1980), and the 
rat (Anderson et al., 1973a; 1975; Anderson and Long, 1978). In addition, 
porcine follicular tissue (Bryant-Greenwood et al., 1980), porcine granulosa 
cells (Loeken et al., 1983), and porcine thecal cells (Evans et al., 1983; Bag-
nell et al., 1987) have been reported to release relaxin immunoreactivity in 
vitro. The placenta has been suggested as the site of relaxin production in the 
rabbit (Fields and Larkin, 1980; Eldridge et al., 1984), horse (Stewart et al., 
1982), and cat (Stewart and Stabenfeldt 1982), as well as the endometrial 
gland as a source of the hormone in the guinea pig (Pardo and Larkin, 1982). 
In the human, relaxin has been found in both the corpus luteum (O'Byrne et 
al., 1978) and placenta (Fields and Larkin, 1981; Yamamoto et al., 1981). 
It was to be more than four decades after its discovery before a pure 
preparation of relaxin was isolated by Sherwood and O'Byrne (1974). Porcine 
relaxin is a polypeptide with an approximate molecular weight of 6,000 dal-
tons consisting of two chains, designated A and B, connected by two interchain 
disulfide bonds. The primary structure of porcine relaxin has been determined 
(Schwabe et al., 1978). The molecule was found to have a certain degree 
of structural homology with insulin and the related growth factors, insulin­
like growth factors (IGF-I and IGF-II) (Bedarkar et al., 1977). Relaxin, like 
insulin, is initially synthesized as a single-chained preprohormone with the 
structure of "signal peptide - B chain - connecting peptide (C-peptide) - A 
chain" (Gast et al., 1980). The entire coding sequence of porcine preprore-
laxin has been determined from cDNA clones (Haley et al., 1982) and the 
gene codes for a 24-amino acid signal peptide, the 32 amino acid B chain, a 
C-peptide of 104 amino acids, and the 22-amino acid A chain. The cDNA 
sequences coding for rat and human preprorelaxins also have been reported 
(Hudson et al., 1981, 1984). Recently, O'Byrne et al (1989) have demon­
strated that blood immunoreactive relaxin in pigs is a secreted biologically 
active form of relaxin with an amino acid composition similar to the form 
stored in the corpus luteum. 
Relaxin acquired its name due to its marked effects on remodelling liga­
ments of the pubic symphysis in the guinea pig. The classic actions of relaxin 
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are exerted on the collagenous structures of the cervix, the pubic symphysis, 
and the smooth muscle or myometrium of the uterus. Relaxin causes suppres­
sion of myometrial contractions during gestation, and relaxation of interpubic 
ligaments and dilation of the cervix at parturition (Porter, 1979). Relaxin is 
necessary for a normal duration of parturition and frequency of live births. 
In the absence of relaxin in the peripheral blood of ovariectomized gilts given 
only progesterone for 10 days before parturition, there results prolonged par­
turition and a high incidence of stillbirths (Nara et al., 1982a); injection of 
relaxin at 6-hour intervals into such gilts results in a normal rapid delivery of 
live piglets. It was demonstrated that the cervical diameter in pregnant pigs 
did not increase until late pregnancy when relaxin levels in the blood were 
elevated (Kertiles and Anderson, 1979). Kertiles and Anderson also found 
that daily intramuscular injections of a small amount of partially purified re­
laxin (about 250 jig daily) beginning on day 105 or 107 induced premature 
cervical dilation in pigs which were luteectomized on day 110. In ovariec­
tomized gilts given progesterone to maintain pregnancy, relaxin treatment 
promotes growth and extensibility in the uterine and vaginal portions of the 
cervix between days 80 and 110 of pregnancy (O'Day et al., 1989). By us­
ing monoclonal antibodies specific for rat relaxin, Sherwood and colleagues 
demonstrated that relaxin is needed during the prepartum period for normal 
cervical growth and extensibility, normal litter delivery and high postpar­
tum pup survival in the rat (Hwang et al., 1989). In beef and dairy cattle, 
porcine relaxin administered during late pregnancy increases both pelvic area 
and cervical dilatation (Anderson et al., 1982; Musah et al., 1986; Bagna 
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et al., 1991). Furthermore, such relaxin treatment causes an acute tran­
sient decrease in blood progesterone concentrations, earlier parturition, and 
a decrease in the incidence of dystocia (Anderson, 1987; Bagna et al., 1991). 
Relaxin combined with cloprostenol, a PGF2(j analog, or dexamethasone, a 
glucocorticoid analog, 10 days before expected parturition decreases the inci­
dence and severity of dystocia, decreases the incidence of retained placenta, 
and also shortens the period from the onset of labor to calving (Anderson, 
1987). Relaxin also has been suggested as a "local" hormone with paracrine 
functions (Bryant-Greenwood, 1982), such as at the level of the fetal mem­
branes or uterus (Koay et al., 1984; Castracane et al., 1984), which could be 
important at parturition, or in the follicle at ovulation (Evans et al., 1983). 
Relaxin may also have a role in the regulation of sperm motility, perhaps 
accounting for its presence in the seminal plasma (Weiss, 1984). These and 
other possible "nonclassical" roles of relaxin remain to be established. 
The corpora lutea in the pig are the principal and, perhaps, the sole source 
of relaxin during the approximately 115-day gestation period. Plasma relaxin 
concentrations remain below 2 ng/ml until about day 100 and then increase 
gradually to approximately 10 ng/ml 3 days before delivery (Anderson et al., 
1983; Sherwood et al., 1975). During the 2 days which precede delivery, re­
laxin blood levels increase rapidly and reach maximal levels that range from 
50 to 250 ng/ml. In most cases, this prepartum surge consists of two or three 
sustained peaks which last for about 10 to 20 hours (Sherwood et al., 1981). 
The final peak which has maximal relaxin concentrations, generally occurs 
14 to 22 hours before parturition (Belt et al., 1971; Sherwood et al., 1975, 
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1976, 1978, 1979, 1981; Taverne et al., 1982). Relaxin levels then declined 
markedly and are extremely low to undetectable during lactation (Sherwood 
et ai., 1981). Peripheral blood relaxin immunoactivity levels throughout preg­
nancy as shown above are consistent with the view that relaxin accumulates 
within the corpora lutea as cytoplasmic granules during most of pregnancy 
and is released during the rapid degranulation which occurs during the 2 days 
before birth (Belt et al., 1971; Anderson et al., 1973b; Kendall et al., 1978; 
Larkin et al., 1983; Fields and Fields, 1985). 
Hysterectomy of nongravid pigs during the early part of the estrous cycle 
sustains luteal function until about day 150 (Adair et al., 1982; Anderson 
et al., 1983; Musah et al., 1984). After hysterectomy, relaxin and proges­
terone levels in peripheral blood as well as the accumulation and depletion 
of the relaxin storage granules in corpora lutea show the patterns similar to 
those of the pregnant gilts at comparable stages, but with consistently higher 
progesterone and relaxin levels and much lower relaxin peaks (Belt et al., 
1971; Adair et al., 1982; Anderson et al., 1983; Felder et al., 1986). Thus, 
the hysterectomized gilt serves as a useful model to examine the mechanisms 
regulating hormonal functions of these aging corpora lutea. 
The factors which promote relaxin synthesis and storage and the mecha­
nisms which regulate relaxin secretion, especially its prepartum peak release 
are not well understood. The evidence that timed peak release of relaxin and 
coincident decrease in progesterone secretion in hysterectomized gilts occur at 
day 113, the same time in pregnant animals just before normal parturition 
indicates that the corpora lutea are undergoing functional regression (i.e., a 
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rapid fall in progesterone levels) while the peak release of relaxin occurs. It 
also suggests that a basic underlying mechanism, independent of the influ­
ence of conceptuses or the uterus, regulates relaxin secretion by aging porcine 
corpora lutea. 
Prepartum relaxin peak levels in blood have been associated with elevated 
prostaglandin F2Q, (PGFg,;^) and the termination of luteal function (Belt et al., 
1971; Sherwood et al., 1978, 1979, 1981; Nara and First, 1981). Injection of 
PG synthesis inhibitors, such as indomethacin, delays luteolysis, the relaxin 
peak and the birth of the piglets (Sherwood et al., 1979; Nara and First, 
1981; Taverne et al., 1982). However, a nonluteolytic dose of PGF2(^ can 
also cause peak relaxin release into peripheral blood within 10 minutes (Nara 
et al., 1982b). The events that bring about luteolysis during late pregnancy 
and after hysterectomy are not known with certainty. During normal preg­
nancy a prepartum peak of relaxin secretion coincides with maturation of the 
porcine fetuses, but it may not be essential for parturition (Kendall et al., 
1988). The fetuses seem to influence the peak relaxin concentrations, which 
reflect litter size. Furthermore, in gilts bearing hypophysectomized fetuses, 
the normal prepartum peak of relaxin is disrupted (Kendall et al., 1988). 
There is a prepartum rise in PRL blood levels which is temporally associated 
with the prepartum peak relaxin levels (Taverne, et al., 1979; Kendall et al., 
1982; Dusza and Krzymowska, 1981); however, PRL does not seem to be re­
quired for the release of relaxin because the administration of bromocriptine, 
an inhibitor of PRL synthesis, prevented the PRL rise, but not the relaxin 
peak before farrowing (Taverne et al., 1982). Furthermore, the peak release 
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of relaxin still occurred on about day 113 after hypophysectomy on day 110 in 
hysterectomized gilts which suggested that pituitary gonadotropins and PRL 
were not involved directly with timed peak release of relaxin from aging cor­
pora lutea (Li, et al., 1989). The prepartum decline in blood progesterone 
levels does not seem to promote the release of relaxin since administration 
of progesterone from days 110-116 delayed delivery but it did not delay the 
prepartum release of relaxin (Sherwood, et al., 1978; Taverne et al., 1982). 
Therefore, the corpus luteum seems to have intrinsic mechanisms for its own 
hormonal regulation that we are only beginning to understand. Because it 
is an ephemeral gland, the corpus luteum has unusual requirements in that 
it must prepare for its own destruction while fulfilling its crucial role of pro­
gesterone and relaxin secretion. It has been postulated that the peak release 
of relaxin and coincident decrease in progesterone secretion are a genetically 
controlled event related to the aging of porcine corpora lutea whose life-span 
is defined through evolutionary development of the reproductive cycle as the 
duration of gestation of about 114 days. The challenge for the future is to dis­
cover those intracellular and intercellular events that allow the corpus luteum 
to play out this scenario. 
RU 486 and Steroid Hormone Receptors 
RU 486, a synthetic steroid produced by ROUSSEL-UCLAF(Paris, France), 
is the first available active antiprogesterone (Baulieu, 1985). Since its intro­
duction in early 80's, it has been used successfully as a medical alternative for 
early pregnancy interruption and for contraception. In addition, the availabil­
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ity of RU 486 offers scientists powerful tool for research into the physiological 
role of progesterone and into the mechanism of action of steroid hormones at 
cellular level. 
In mammals, progesterone is essential for the establishment and main­
tenance of pregnancy. Progesterone promotes the secretory function of the 
endometrium to ensure the implantation and nourishment of the embryo, 
and it inhibits or reduces the contractile responsiveness of myometrium to 
excitatory agents such as prostaglandins or oxytocin, thereby protecting the 
developing embryo and fetus. Progesterone exerts most of its activity through 
binding to a specific intracellular protein termed progesterone receptor (Mis-
rahi et al., 1990). RU 486 is a progesterone receptor antagonist that renders 
progesterone biologically inactive. RU 486 also possesses antiglucocorticoid 
properties (Healy et al., 1985; Gaillard et al, 1984). 
Progesterone receptors have been found in uterine endometrium and my­
ometrium, where their concentrations are under the control by estrogen. Pro­
gesterone receptors are also present in Fallopian tube, pituitary, hypothala­
mus, cerebral cortex, vagina, testis, thymus, and mammary gland (Savouret 
et al., 1988). According to the classic model, receptors of steroid hormones 
were defined as saturable cytosolic binding proteins with high and specific 
affinity for their ligands; the hormone bound its receptor upon entry into the 
cytoplasm, activated it and induced its transfer to the nucleus where subse­
quent regulation of specific genes would take place. This classic model was 
made obsolete 7 years ago when King and Greene (1984) reported that unoc­
cupied estradiol receptors were loosely bound to the nucleus and only released 
12 
into the cytosol by extraction. With the production of specific antireceptor 
antibodies and the development of immunocytochemical techniques, receptors 
for steroid hormones (including progesterone, estrogen, androgen, glucocorti­
coid, and vitamin D) have all been located primarily in the nucleus even in 
the absence of hormone treatment (Carson-Jurica et al., 1990). 
Steroid receptors belong to, both structurally and functionally, a super-
family of proteins. The rapid development of molecular biology has allowed 
the cloning of steroid receptors (including those for progesterone, estrogen, 
androgen, glucocorticoid, vitamin D, and thyroid hormones) from a number 
of different species. As a result, advancement in our understanding of the 
structure-function relationships for these molecules has been dramatic. A 
steroid receptor is composed of three distinct domains having separable func­
tions; hormone binding, DNA binding, and immunoreactivity. The hormone 
binding domain is at the carboxy terminal end of the protein with the DNA 
binding domain being nearer to the amino terminus. The sizes of these two 
domains are relatively similar for different steroid receptors and the major 
heterogeneity is due to immunogenic domain of ill-defined function. Many of 
the antibodies récognize epitopes in an immunogenic domain (King, 1987). 
In the absence of steroid hormones, steroid receptors are inactive and it 
has been proposed, therefore, that the hormone binding domain serves as a 
repressor of receptor functions (Carson et al., 1987; Hollenberg et al., 1987; 
Godowski et al., 1987). This repression may be accomplished by a different 
mechanism. The domain itself might block DNA binding and gene activa­
tion by maintaining the receptor in an inactive conformation. Binding of the 
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hormone would result in a change in the conformation of the receptor such 
that functional domains are now exposed. The other possible mechanism of 
repression would involve interaction of the steroid binding domain with other 
cellular proteins which would maintain the receptor in an inactive form. It 
has been proposed that interaction with a 90 kilodaltons heat shock protein 
(HSP 90, an abundant cytosolic protein) is the mechanism by which the hor­
mone binding domain represses receptor function (Picard et al., 1988; Denis 
et al., 1988; Gustafsson et al., 1989). Binding of a hormone would result in 
the dissociation of HSP 90, allowing the receptor to bind DNA. Unlike other 
steroid receptors, however, vitamin D or thyroid receptors are not associated 
with HSP 90 (Carson-Jurica et al., 1990). 
Steroid hormones modulate transcription of target genes by their interac­
tion with enhancer-like specific gene sequences known as hormone responsive 
or regulatory elements (HRE) located in the regulatory regions 5' to the struc­
tural gene (Yamamoto, 1985). The DNA binding domain of steroid receptors 
contains a high concentration of cysteine residues. It has been suggested that 
two sets of 4 cysteine residues in coordination with 2 zinc atoms cause the 
formation of 2 loop projections from the DNA binding domain. These loops 
have been termed "zinc fingers" or "DNA binding fingers" and they appear 
to be responsible for the binding of receptor to HRE on DNA (Umesono and 
Evans, 1989). In order to determine whether functional domains could act 
when placed within heterologous steroid receptors, chimeric proteins were 
created in which the hormone and DNA binding domains from different re­
ceptors were exchanged. A particularly dramatic example of this approach is 
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the replacement of the DNA binding domain of estrogen receptor with same 
domain of glucocorticoid receptor; the hybrid estrogen receptor, in the pres­
ence of estradiol, behaves as a glucocorticoid receptor (Green and Chambon, 
1987). Thus, DNA binding domain seems to determine specificity of function, 
or the type of response to a given steroid is determined by the HRE of genes 
and not the receptor. 
The ultimate function of receptors is to elicit specific effects at the tran-. 
scriptional level. It has been shown that multiple regions of the receptor, both 
N-terminal and C-terminal, are involved in the transcriptional activation pro­
cess (Carson-Jurica et al., 1990). These transcription activation domains are 
therefore located within the DNA binding and hormone binding domains. 
Steroid receptors have been shown to be phosphoproteins. The phospho­
rylation and dephosphorylation process has been suggested to be a control 
mechanism for the regulation of transformation, hormone binding, DNA bind­
ing, and transcriptional activation (Carson-Jurica et al., 1990). 
The mechanism of action of RU 486 at the cellular and molecular lev­
els has not been fully elucidated. RU 486 is thought to stabilize the het-
erooligomer formed by progesterone receptor and HSP 90 (heat shock protein 
90) and thereby block the interaction between the receptor and HRE (hormone 
responsive element) on DNA (Groyer et al., 1987; Baulieu, 1988, 1989). Al­
ternatively, the RU 486-receptor complexes may not be active because of a 
lack of appropriate conformational changes; or the complexes may bind to 
HRE, which has been demonstrated (Bailly et al., 1986; Guiochon-Mantel et 
al., 1988), but unlike the agonist-receptor complexes, are unable to promote 
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the gene transactivation. 
RU 486 is proving to be powerful tool for the study of hormone-receptor 
interaction and for exploring the physiological role of progesterone. For exam­
ple, RU 486 was shown to block the inhibitory effect of progesterone on PRL 
secretion stimulated by estrogen in the rat, which confirmed the physiological 
significance of the finding that progesterone has a specific effect in reducing 
estrogen receptor level in the pituitary gland (Brann et al., 1988). A role 
for progesterone, in modulating the preovulatory surge of gonadotropins and, 
consequently, ovulation, was strongly suggested by the use of RU 486 (Rao 
and Mahesh, 1986). 
Endocrine Control of Pregnancy and Parturition in the Pig 
The gestation period in swine is usually 113-115 days. A feature unique 
to the pig is its dependence on the corpora lutea for the production of proges­
terone throughout pregnancy; ovariectomy, or any other manipulation which 
suppresses luteal function terminates pregnancy within 2 days (Belt et al., 
1971; Nara et al., 1981). After the preovulatory luteinizing hormone (LH) 
surge, the corpora lutea of pigs survive for about 2 weeks, unaffected by either 
hypophysectomy or pituitary stalk section, in either pregnant or non-pregnant 
animals (du Mesnil du Buisson and Leglise, 1963; Anderson et al., 1967; du 
Mesnil du Buisson and Denamur, 1969), indicating that once formed, the 
porcine corpora lutea do not require luteotropic support up to about 2 weeks. 
The porcine corpora lutea are refractory to the luteolytic effect of PGF2Q 
for about 12 days after the onset of estrus (Diehl et al., 1974; Moeljono et 
al., 1976). Endometrium-blastocyst interactions begin to occur by day 11 of 
pregnancy. Blastocysts signal their presence, presumably through estrogen 
production, which results in the maintenance of corpora lutea. Estrogen, of 
blastocyst origin, allows for the continued secretion of PGEgg, from uterine 
endometrium, but in an exocrine direction into the uterine lumen, instead 
of in an endocrine direction toward uterine vascular beds which would oth­
erwise initiate luteolysis as seen during an estrous cycle. This mechanism 
appears to be essential for the establishment of pregnancy in pigs (Bazer and 
Thatcher, 1977). Beyond this time, pituitary hormones are required for the 
maintenance of corpora lutea during pregnancy (Kraeling and Davis, 1974). 
Both LH and PRL have been implicated as important luteotropic hormones. 
However, several lines of evidence suggest that the luteotropic requirements 
change during the course of gestation, with the predominant support provided 
by LH until mid-gestation and PRL being more important thereafter (Ander­
son et al., 1965, 1967; du Mesnil du Buisson and Denamur, 1969; du Mesnil 
du Buisson, 1973). Daily injections of highly purified porcine PRL (2.0 mg/day 
from days 110 to 120) prolong the secretory function by aging corpora lutea 
with sustained relaxin and progesterone secretion in pregnant and hysterec­
tomized gilts (Felder et al., 1988). The same PRL treatment maintains both 
progesterone and relaxin secretion as well as the morphology of aging corpora 
lutea for at least 10 days after hypophysectomy in hysterectomized gilts (Li 
et al., 1989). 
Since progesterone is the principal factor maintaining, pregnancy and the 
corpora lutea are the main source of progesterone, termination of luteal pro­
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duction of progesterone is necessary before parturition can occur. PGF2(^ of 
uterine origin has also been implicated as a natural luteolytic agent at term 
(Nara and First, 1981). However, experimental results inconsistent with this 
view have also been produced (Gooneratne et al., 1983). 
Parturition is preceded by a multitude of hormonal changes in the ma­
ternal blood, which include increased concentrations of estrone and estradiol, 
relaxin, corticosteroid, PRL, PGFg,^ and its metabolite, and oxytocin. Al­
though the initiation of the prepartum maternal endocrine changes and the 
eventual parturition in the pig are not completely understood, compelling ev­
idence suggests that fetuses play important roles, as they do in sheep, rab­
bits and goats (First and Bosc, 1979). This control may be through a fetal 
hypothalamus-pituitary-adrenal system. Fetal brain and pituitary gland are 
implicated as the source of impetus for initiation of parturition, since decapita­
tion (Stryker and Dziuk, 1975; Coggins and First, 1977), or hypophysectomy 
(Bosc et al., 1974) of the piglets in utero prolonged pregnancy and caused 
maintenance of progesterone production. Decapitated or hypophysectomized 
fetuses may have failed to induce parturition because their adrenal glands 
were atrophied and produced little Cortisol (Stryker and Dziuk, 1975; Bosc 
et al., 1974). Adrenal weights and Cortisol concentrations in pig fetuses nor­
mally increase rapidly preceding parturition (Bosc, 1973; Fevre et al., 1975). 
Exogenous adrenocorticotropic hormone (ACTH) given to pig fetuses (Bosc, 
1973), or dexamethasone, a synthetic glucocorticoid, given to the fetuses or 
the mother (Coggins and First, 1977; Huhn et al., 1978) induced parturition 
which was accompanied by live births and milk ejection. In addition, dex-
amethasone caused a rapid decline in plasma progesterone during the 2 days 
preceding parturition similar to that occurring after treatment or at 
a normal parturition (Coggins and First, 1977) 
Glucocorticoids induce parturition in the pig by causing an increase in 
uterine PGF2(j secretion, which in turn brings about luteolysis. Treatment 
with indomethacin, an inhibitor of PG synthesis, alone or indomethacin plus 
dexamethasbne prolonged gestation and prevented an increase in PGF2(j-
metabolite and a decrease in progesterone (Nara and First, 1981). Whether 
the effect of glucocorticoids on the synthesis of PGF2Q, occurs by direct stim­
ulation of the PG-synthetase enzyme system or is mediated by other agents 
remains to be determined. How the fetal brain controls the fetal adrenal 
is not yet well known. In addition to ACTH, some other hormonal and/or 
neural factors, such as a-melanocyte stimulating hormone (q-MSH), hypotha­
lamic corticotropin releasing factor (CRF) may be involved. Furthermore, 
the control of adrenal Cortisol production by the fetal pituitary may not be 
the only way that triggers parturition, since parturition in pigs was not in­
duced by the maternal administration of dexamethasone until after day 100 
of gestation (Coggins, 1975), and dexamethasone injected after day 100 was 
incapable of inducing parturition when fetuses were decapitated (Coggins and 
First, 1977). ACTH given to the fetuses also failed to induce parturition until 
day 100 (Bosc, 1973). These facts imply that a target for the glucocorti­
coids, must be developed before dexamethasone can induce parturition, and 
the entire conceptus must reach a certain stage of maturity before fatal or 
exogenous glucocorticoids can initiate the sequence of events that culminate 
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in parturition. 
The precisely timed prepartum surge release of relaxin in the pig may 
contribute to the timing of birth by suppressing central release of oxytocin 
via the activation of opioid mechanisms (Anderson, 1987). Intravenous infu­
sion of relaxin has been shown to elicit growth hormone and PRL secretion 
in monkeys (Bethea et al., 1989). These results suggest that in addition to 
its well-known peripheral actions on the myometrium, cervix, and pubic sym­
physis, relaxin can act at the level of central nervous system to affect the 
secretory functions of hypothalamus and pituitary gland. 
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SECTION I. DIVERGENT EFFECTS OF ANTIPROGESTERONE, RU 
486, ON PROGESTERONE, RELAXIN AND PROLACTIN 
SECRETION IN PREGNANT AND HYSTERECTOMIZED PIGS 
WITH AGING CORPORA LUTEA 
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ABSTRACT 
Porcine corpora lutea produce progesterone and relaxin during pregnancy 
and after hysterectomy. Peak amounts of relaxin are released into periph­
eral blood in both pregnant and hysterectomized animals on about day 113 
(estrus = day 0 and term = 114), and this release coincides with an abrupt 
decrease in the progesterone concentration. RU 486, a progesterone receptor 
antagonist, was used to investigate the effects of interruption of progesterone 
binding to its receptor on luteal function and gonadotropin secretion of pigs 
with aging corpora lutea. RU 486 was administered orally to hysterectomized 
gilts (surgery on day 8) once a day (0800 h) on days 111-115 at two dosages 
(group 1, 2 mg/kg BW; group 2, 4 mg/kg BW). During 5 days of RU 486 
treatment, plasma progesterone concentrations in both treated groups were 
markedly elevated (32 and 37 ng/ml for groups 1 and 2) compared with 22 
ng/ml in the controls (group 3; f <0.01). PRL concentrations increased in both 
groups (9 and 13 ng/ml) and differed significantly from those of the controls (3 
ng/ml) (f <0.04). RU 486 treatment delayed the time of relaxin peak to days 
116.1 and 117.0 in groups 1 and 2 compared with day 114.1 in the controls 
(f <0.01). Pi-egnant gilts received RU 486 orally once a day (0800 h) at 4 
mg/kg BW beginning on day 111 until parturition occurred. Parturition was 
induced on day 112.7 after only two RU 486 treatments compared with day 
114.7 in the control group (f <0.01). Progesterone decreased abruptly from a 
pretreatment mean of 11 to < 0.6 ng/ml during the 2 days that RU 486 was 
given compared with a shift from 12 to 6 ng/hil during the same period in the 
controls (f <0.01). The time of the relaxin peak was advanced to day 112.1 
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in RU 486 treated gilts compared with day 113.9 in the controls (f <0.01). 
Results from this study provide strong evidence that the antagonistic effect 
of RU 486 on progesterone receptor results in an abrupt increase in PRL and 
progesterone secretion in hysterectomized gilts with aging corpora lutea. In 
marked contrast with hysterectomized animals, the acute luteolytic effects of 
RU 486 depend on the presence of the uterus and/or conceptuses in the pig. 
Disruption of the regulatory loop of progesterone secretion by RU 486 alters 
the ability of corpora lutea to produce and release peak quantities of relaxin. 
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INTRODUCTION 
RU 486 (11/5 - [4-dimethylamino phenyl] - 17/3-hydroxy-17a - [1-propynyl] 
- estra-4, 9-dien-3-one) acts with high affinity as an antagonist for proges­
terone receptor, and allows a novel approach for determining the physiologi­
cal role of progesterone in regulating the hypothalamus-pituitary-gonadal axis 
(Baulieu, 1989; Moguilewsky and Philibert, 1987 ). RU 486 also has antiglu-
cocorticoid activity (Healy et al., 1985; Gaillard et al., 1984). 
Pregnancy lasts about 114 days in pigs. The maintenance of pregnancy 
depends on the production of progesterone by corpora lutea in the ovaries 
(Nara et al., 1981). Corpora lutea of the pig produce not only progesterone 
but also relaxin, a peptide hormone that plays a critical role in suppress­
ing uterine motility during pregnancy and in remodeling connective tissues in 
preparation for imminent parturition (Anderson, 1987). Progesterone concen­
trations in peripheral blood remain elevated (%18 ng/ml) for the major part of 
pregnancy and decrease just before parturition. The decrease in progesterone 
coincides with a peak prepartum release of relaxin into the blood (Belt et al., 
1971; Sherwood et al., 1981; Felder et al., 1986). Corpora lutea of pigs hys­
terectomized during the early part of. a 21-day estrous cycle are maintained 
until day 150, and produce progesterone and relaxin in a similar manner (i.e., 
a surge release of relaxin and a coincident decrease in progesterone on day 
113) as is seen in normal pregnant animals (Felder et al., 1986). Mechanisms 
regulating such precisely timed events in both pregnant and hysterectomized 
pigs are undefined. Our recent results indicate that purified porcine PRL is 
luteotropic for aging corpora lutea in the pig, and that the timed peak release 
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of relaxin into blood remains unchanged despite hypophysial stalk transection 
or hypophysectomy (Felder et al., 1988; Li et al., 1989). 
In this experiment, we used RU 486 as a probe to gain insight into the 
roles of progesterone in the modulation of aging luteal cell function during 
a critical period when markedly abrupt changes occur in progesterone and 
relaxin secretion in both pregnant and hysterectomized pigs. The objectives 
were to determine the effects of RU 486 administration on endogenous secre­
tion of progesterone, relaxin and PRL, and on the induction of parturition. 
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MATERIALS AND METHODS 
Animals 
Purebred Yorkshire gilts (8 months old, =130 kg BW) that had exhibited 
at least one normal estrous cycle (19-23 days) were used in this experiment. 
Pregnancy was achieved by natural mating at estrus (day 0) by Yorkshire 
boars with proven fertility. Hysterectomy was performed on day 8 of the 
estrous cycle by midventral laparotomy (Anderson et al., 1961). Cannula-
tion (Tygon microbore tubing; id, 1.27 mm; od, 2.29 mm; Fisher Scientific, 
Pittsburgh, PA) of the cranial vena cava was performed by the techniques 
described by Ford and Maurer (1978) on day 98 for repeated blood sample 
collections that began on day 100. 
Experimental Groups 
For hysterectomized pigs, two dosages of RU 486 were orally administered 
to randomly assigned animals in group 1 (2 mg/kg BW; n = 5) and group 
2 (4 mg/kg BW; n = 7) once a day from days 111-115. Group 3 (n = 6) 
served as hysterectomized controls with no drug treatment. Pregnant pigs 
were randomly divided into one treated group (n = 6) that received RU 486 
(4 mg/kg BW) once a day beginning on day 111 until parturition and one 
control group (n = 5). RU 486 was mixed with a small amount of granular 
feed and given to the pigs at 0800 h before normal feeding time which was 
at 0900 h each day. All feed mixed with RU 486 was consumed by the pigs 
within 20 min. The placebo treated controls were given the same amount 
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of feed without the drug at those times. The pigs were observed throughout 
the 24-h period of each day for imminent signs of parturition; this allowed an 
accurate determination of the time between the start of hormone treatment 
and the onset of parturition. 
Blood samples were collected once a day at 0800 h from days 100T109, 
4 times a day at 6-h intervals from days 110-116, and once a day at 0800 
h from days 117-120. All blood samples (10 ml) were collected in disposable 
borosilicate culture tubes (16 x 100 mm) containing 0.2 ml heparin sodium 
salt solution (100 lU/ml; NBCO Biochemicals, Cleveland, OH) and immedi­
ately centrifuged (2000 x g) for 10 min. Plasma was decanted and stored at 
-20°C until required for RU 486, progesterone, relaxin, and PRL RIAs. 
RIAs of RU 486, Progesterone, Relaxin, and PRL in Peripheral Plasma 
RU 486 concentrations were determined by RIA procedures as previously 
described (Salmon and Mouren, 1985; Heihinheimo et al., 1986) with mod­
ifications. Tritiated RU 486 (46.8 Ci/mmol) was a gift from Dr. A. Jacot, 
Roussel-UCLAF. The anti-RU 486-3-carboxymethyloxime-BSÀ antiserum (a 
gift from Dr. D. Philibert, Roussel-UCLAF) was raised in New Zealand White 
rabbits according to previously described methods (Raynaud et al., 1974). 
Plasma samples (50 //I) in duplicate were added to 0.25 ml double distilled 
water and extracted with 3.0 ml diethyl ether (spectrophotometric grade, 
Aldrich, Milwaukee, WI). The recovery of radioactivity after extraction av­
eraged 85%. The total incubation volume was 0.4 ml/tube in which anti­
serum was diluted to 1:10,000 and total "^H-RU 486 was 10,000 cpm. The 
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standard curve contained 0, 20, 40, 80, 125, 250, 500, 1,000, and 2,000 
pg/tube RU 486 in triplicate, respectively. Separation of unbound fraction 
was obtained by dextran-coated charcoal. The sensitivity of the assay was 
10 pg/tube, and the inter- and intraassay coefficients of variation were 16.2% 
(n = 4 assays/sample) and 8.2% (n = 6 samples), respectively; nonspecific 
binding was 6.1%. 
Relaxin was quantified in duplicate 200-//1 aliquots of plasma by using a 
homologous double-antibody RIA for porcine relaxin as described previously 
(Li et al., 1989; O'Byrne and Steinets, 1976). The sensitivity of the assay was 
40 pg/tube. The inter- and intraassay coefficients of variation were 11.7% (n 
= 3 assays/sample) and 4.8% (n = 6 samples); nonspecific binding was 2.7%. 
Progesterone was determined in duplicate 100-//1 aliquots of plasma ac­
cording to RIA procedures described previously (Li et al., 1989)) with the 
same fully characterized antibody (GDN-337) (Niswender, 1973; Gibori et 
al., 1977). Recovery after extraction with benzene-hexane was 89%, and the 
minimal detectable concentration of progesterone was 50 pg/tube. The inter-
and intraassay coefficients of variation were 13.3% (n = 5 assays/sample) and 
,9.8% (n = 6 samples), respectively; nonspecific binding was 3.2%. 
The. PRL concentration in plasma was quantitated by double antibody 
homologous RIA, as described previously (Li et al., 1989). The radioiodination 
preparation was USDA pPRL II (potency, 103 lU/mg), and USDA pPRL B1 
(potency, 34 lU/mg) was used as the reference preparation. The sensitivity 
of the assay was 0.7 ± 0.25 ng/ml (mean ± SD; n = 5), and the inter- and 
intraassay coefficients of variation were 14 ± 3.7% (mean ± SD; 2 samples; 5 
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assays) and 7.4 ± 5.5% (mean ± SD; 2 samples per assay; 2-4 determinations). 
Statistical Analyses 
Experimental units were the individual pigs, which were assigned to 
treatments at random. Data were analyzed by a split-plot analysis of vari­
ance. The main plot effect was treatment tested against pig within treat­
ment (i.e., pig to pig variation) as the whole plot error term. The individual 
temporal sampling times, which were repeated measures on the same pigs 
and resultant interaction with treatment comprised the subplot portion of the 
analysis. Student's t test was used for comparisons between treatment groups 
(Snedecor and Cochran 1980; Spector et al., 1985). 
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RESULTS 
Effects of RU 486 on Induction of Parturition 
In pregnant pigs given RU 486, parturition occurred on day 112.7 after 
only two RU 486 treatments compared with day 114.7 in placebo treated con­
trols (Table 1). RU 486 given during late pregnancy caused normal delivery 
of the piglets within 34 h after the first hormone treatment compared with 
82 h in controls. The numbers of live born piglets, and maternal behavior and 
lactation were similar in the two groups (Table 1). 
RU 486 Concentrations in Peripheral Plasma 
In the pregnant pigs that received the 4 mg/kg BW dose, RU 486 increased 
to peaks of 77 and 55 ng/ml soon-after feeding and was maintained at > 
10 ng/ml 2 days after the second feeding (Figure lA). Circulating RU 486 
concentrations averaged 45 ng/ml at the time of induced parturition. 
There were dose dependent increases in plasma concentrations of RU 486 
after oral intake of the drug in hysterectomized animals. At 2 mg/kg BW, RU 
486 increased to peaks of 20-43 ng/ml within 2 h after each feeding and was 
maintained at %21 ng/ml during the 5-day period of treatment (Figure 2A, 
center panel). When the dosage of RU 486 was doubled (4 mg/kg BW), the 
RU 486 peaks increased markedly compared with the 2 mg/kg dose (P<0.01) 
and ranged from 65 to 110 ng/ml, with a mean of 75 ng/ml during the same 
treatment period (Figure 2A, right panel). 
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Table 1. Induction of parturition with RU 486 in late pregnant pigs 
Placebo control^ RU 486® 
No; of pregnant gilts 5 6 
Time of parturition (days 
after mating) 
114.7 
CO o
 
+
1 
112.7 ± 0.2 b 
Hours from first treatment 
to delivery 
82 ± 7.2 34 ± 4.8 b 
No. of live-bom piglets 9 ± 1.5 8 ± 2.1 
Values are the mean ± SE. 
^ RU 486 at a dosage of 4 mg/kg BW was given orally at 0800 h 
on days 111 and 112 after mating. The controls were given the same 
amount of feed without the drug at those times. 
^ Differs from control (P < 0.01). 
Figure 1. Concentrations of RU 486 (A), progesterone (B), relaxin (C), 
and prolactin (D) in peripheral plasma of pregnant pigs. O, 
Pretreatment (n = 11); •, treatment with RU 486 (4 mg^g BW 
once per day from days 111-112, as indicated by arrows; n = 6); 
0, untreated control (n = 5). Values are the mean ± SE 
Prolactin (ng/ml) Relaxin (ng/ml) 
â ê S § S g I Progesterone (ng/ml) 
Figure 2. Concentrations of RU 486 (A), progesterone (B), relaxin (C), and prolactin (D) in peripheral 
plasma of hysterectomized pigs. 0, Pretreatment (n = 18); •, placebo-treated control (group 3; 
n = 6; left panel); •, treatment with RU 486 (group 1, 2 m^g BW once per day from days 111 
115, as indicated by arrows; n = 5; center panel); •, treatment with RU 486 (group 2,4 mg/kg 
BW once per day from days 111-115, as indicated by arrows, n = 7; right panel). Values are 
mean ± SE 
nu 486 
R O ^ A I O O Q M ^  
D O O O O O O O 
Relaxin (ng/ml) Progesterone (ng/ml) Pfolaclin (ng/ml) 
O R J ^ O > O > O R O A O > C D  
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Progesterone Concentrations in Peripheral Plasma 
Progesterone in pregnant animals decreased abruptly from a pretreat-
ment concentration of 11 ± 0.4 ng/ml (mean ± SE) to a basal level of 0.6 
ng/ml within 2 days after first RU 486 treatment (Figure IB; f <0.01). Pro­
gesterone averaged 6 ± 1.3 ng/ml at the same time (day 112) in the controls 
and reached basal concentration of 0.6 ng/ml by day 115, just after parturition 
(Figure IB). After this sudden decrease in circulating progesterone, an earlier 
parturition in the hormone treated group occurred. 
In sharp contrast, progesterone in the two RU 486 treated groups of hys­
terectomized pigs was markedly elevated (f <0.01) in a dose-dependent man­
ner during 5 days of treatment as compared with the decreasing hormone 
concentrations in the hysterectomized controls (Figure 2B). The mean concen­
trations of progesterone for the 2 mg/kg, the 4 mg/kg, and the control groups 
were 32 ± 1.2, 37 ± 1.7, and 22 ± 0.9 ng/ml, respectively. 
Relaxin Concentrations in Peripheral Plasma 
In pregnant gilts, relaxin remained low at =5 ng/ml from days 100-108 
and then increased gradually, with a surge release of 73 ± 7 ng/ml on day 
113.9 ± 0.3, about 14 h before parturition in the control group (Figure 10). 
Treatment with RU 486 advanced the surge release of relaxin to day 112.1 
±0.2 (P<0.01) with a greater amplitude of this hormone than that in the 
controls (116 ± 16 ng/ml; f <0.04; Figure IC), and parturition followed 18 h 
after the relaxin peak. 
In hysterectomized animals, the surge release of relaxin into peripheral 
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blood at 18.7 ± 2.5 ng/ml occurred on day 114.1 ± 0.7 in the control group 
(Figure 2C, left panel), about the same time as the relaxin peak in the preg­
nant controls (days 113.9 ± 0.3; Figure IC). In marked contrast, 5 days of 
RU 486 treatment in the hysterectomized gilts delayed the occurrence of re­
laxin peaks to days 116.1 ± 0.6 and 117.0 ± 0.7 in the 2 mg/kg and 4 mg/kg 
groups (P<0.01; Figure 2C, center and right panels), respectively, compared 
with the hysterectomized controls. The amplitude of relaxin peaks in the RU 
486 treated groups (13.2 ± 1.3 and 16.2 ± 1.9 ng/ml), however, did not differ 
from that of the controls (18.7 ± 2.6 ng/ml; f >0.20). 
PRL Concentrations in Peripheral Plasma 
The average concentration of PRL was 12 ng/ml from days 100- 110 in 
pregnant animals and increased gradually as pregnancy advanced (Figure 
ID). The peak amount of PRL (%75 ng/ml) in the control group was released 
just before and during parturition and coincided with the relaxin peak (Figs. 
1, C and D). RU 486 treatment did not further increase the elevated PRL 
concentrations but caused an earlier surge release of the hormone (Figs. 1, C 
and D). 
In contrast, PRL concentration in hysterectomized pigs remained at about 
4 ng/ml throughout days 100-120 in the control group (Figure 2D, left panel). 
RU 486 treatment caused an abrupt PRL increase, which was maintained 
during the 5 days of treatment in both groups (9 ± 0.7 and 13 ± 4.1 ng/ml in 
the 2 and 4 mg/kg groups. Figure 2D, center and right panels compared with 
3 ± 0.4 ng/ml in the controls; f <0.01). Furthermore, PRL remained elevated 
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until day 120 in the 4 mg/kg group. 
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DISCUSSION 
As summarized in Figure 3, divergent results were obtained with RU 486 
in the two animal models used in this study with respect to progesterone and 
relaxin secretion. In pregnant pigs, RU 486 caused a premature release of 
peak relaxin and an acute luteolysis as evidenced by an abrupt decrease in 
circulating progesterone concentrations and an earlier parturition than that 
in placebo treated controls (Figure 3, A and C). In contrast, the same RU 486 
treatment in hysterectomized pigs delayed the peak release of relaxin and 
a markedly stimulated progesterone secretion in a dose-dependent manner 
compared with that seen in the placebo treated controls (Figure 3, B and D). 
There are additional important differences in the inherent abilities of aging 
corpora lutea to secrete relaxin and progesterone from days 100-120 in preg­
nant and hysterectomized pigs. For example, during the pretreatment period 
(days 100-110) the gradual increases in relaxin plasma concentrations are sirti-
ilar in both groups (Figure 3, A and B), whereas progesterone concentrations 
are consistently greater (28 vs 11 ng/ml) in hysterectomized than in preg­
nant animals (Figure 3, C and D). Furthermore, as was reported previously 
(Felder et al., 1986), progesterone concentrations decrease in hysterectomized 
gilts from day 111 onward. Although the precise timing of the inherent re­
laxin release in placebo-treated hysterectomized gilts is the same as that in 
placebo-treated pregnant animals, the magnitude of the relaxin peak (19 vs 72 
ng/ml) is smaller and the circulating levels of the hormone remain consistently 
greater (8 vs < 0.5 ng/ml) in hysterectomized than in pregnant/lactating gilts 
up to day 120. 
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Figure 3. Comparison between pregnant pigs and hysterectomized pigs 
of relaxin and progesterone concentrations (A and C, pregnant 
pigs; B and D, hysterectomized pigs). RU 486 treatment (4 
mg/kg BW once per day at 0800 h for both pregnant and 
hysterectomized pigs) is indicated by two or five consecutive 
arrows, and the time of parturition is indicateed by arrows for 
RU 486 (Trt) and placebo (Cont)-treated groups during, late 
pregnancy. O, Pretreatment (pregnant pigs, n = 11; 
hysterectomized pigs, n = 18); •, RU 486 4 mg/kg BW 
(pregnant pigs, n = 6; hysterectomized pigs, n = 7); #, placebo-
treated control (pregnant pigs, n = 5; hysterectomized pigs, n = 
6). Values are mean ± SE 
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In the mammaUan uterus, progesterone binds with its receptor to cause 
endometrial proliferation of epithelial, glandular, mesenchymal, and vascu­
lar cells, and such binding is required to maintain pregnancy to normal term 
(Carson-Jurica et al., 1990). RU 486 interrupts early pregnancy in rats, mice, 
guinea pig, rabbits, dogs, macaque monkeys, and women at doses of approx­
imately 10 mg/kg BW per day for 1-4 days (Couzinet et al., 1986; Shoupe et 
al., 1987; Philibert et al., 1985). The abortifacient actions of RU 486 may 
result from an interplay of prostaglandins, glucocorticoids, and oxytocin on 
the maternal uterus and cervix for expulsion of the conceptus(es). RU 486 
and other norsteroid antigestagens, such as ZK 98.774, ZK 98.229, and ZK 
112.993, have been used to induce parturition in laboratory animals and pigs 
(Van Look and Bygdeman, 1989). In cattle and sheep, RU 486 given dur­
ing late pregnancy abruptly decreased progesterone secretion and effectively 
induced parturition without the detrimental effects of dystocia, retention of 
placental membranes, and delayed postpartum fertility (Li et al., 1991; Gazai 
et al., 1991). A feature unique to the pig is its absolute dependence on corpora 
lutea for the production of progesterone throughout pregnancy; ovariectomy 
at any time results in abortion within 36 h (Nara et al., 1981; Belt et al., 
1971). Thus, an acute decrease in circulating progesterone concentrations is 
a prerequisite for parturition in this species. Although the exact mechanism 
responsible for the abrupt luteolytic action of RU 486 in pregnant pigs is un­
known, it probably results from RU 486's action through the uterus and/or 
conceptuses, because in the absence of uterus (i.e., after hysterectomy), luteal 
function was stimulated by the same RU 486 treatment. RU 486 promotes 
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prostaglandin F2Q, (PGF2Q,) production in vivo in the rat uterus, and in vitro 
in the endometrial cells and decidual glandular cells from humans (Seddhi 
et al., 1985; Kelly et al., 1986;. Smith and Kelly, 1987). Acting also as an 
antiglucocorticoid compound, RU 486 disrupts the negative feedback loop of 
hypothalamus-pituitary-adrenal axis and results in the elevation of blood con­
centrations of Cortisol and ACTH in laboratory animals and humans (Healy 
et al., 1985; Gaillard et al., 1984; Spitz et al., 1985). Both and glu-
cocorticords would bring about the premature demise of corpora lutea and, as 
a result, a rapid drop in circulating progesterone and an advanced release of 
peak relaxin into the blood. 
Gonadal steroids are known to be actively involved in the regulation of 
gonadotropins (FSH and LH) and PRL secretion (Brann and Mahesh, 1991). 
In the absence of a uterus, RU 486 may act primarily at the level of the hy­
pothalamus and/or pituitary gland to affect PRL and gonadotropin secretion. 
Several lines of evidence have demonstrated that PRL is luteotropic in the pig 
during the later part of pregnancy and after hysterectomy (Anderson et al., 
1967, 1972; du Mesnil du Buisson and Denamur, 1969; Rolland et al., 1976; 
Bramley and Menzies, 1987). PRL alone is sufficient to maintain elevated cir­
culating concentrations of progesterone and relaxin from aging corpora lutea 
in hysterectomized pigs after hypophysectomy (Li et al., 1989). Estrogens are 
potent stimulators of PRL secretion, and they are known to increase adenohy-
pophyseal PRL content, pituitary gland weight, and circulating PRL concen­
trations in pigs (Anderson et al., 1972; Stevenson et al., 1981). Higher blood 
concentrations of PRL in females than in males may result from a greater 
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output of estrogens in females. Estrogens act directly on pituitary lactotropes 
counteracting dopamine, reduce hypothalamic dopamine and norepinephrine, 
and perhaps influence opioid production (Leong et al., 1983; Ben-Jonathan, 
1985). Estrogens act via specific nuclear binding sites and induce PRL mRNA 
synthesis. Progesterone has an inhibitory effect on PRL secretion by coun­
teracting estrogen action in the anterior pituitary where it depletes nuclear 
estrogen receptor (Smanik et al., 1983; Brann et al., 1988; Fuentes et al., 
1990). RU 486, acting as a progesterone receptor antagonist, disinhibits the 
action of progesterone (Brann et al., 1988). In the present study with hys­
terectomized pigs, RU 486 treatment could have rendered progesterone inef­
fective in opposing the action of estrogens and thus resulted in an increase in 
PRL secretion due to the unopposed estrogen action, even though circulating 
concentrations of 17/9-estradiol and estrone are consistently low in hysterec­
tomized pigs compared with those in pregnant pigs (Anderson et al., 1983). 
High circulating concentrations of PRL in this study may have contributed 
to the stimulation of progesterone secretion. Administration of RU 486 also 
resulted in significant increases in serum PRL in rats and humans (Shoupe et 
al., 1987; Rao and Mahesh, 1986). In contrast, despite increased PRL secre­
tion in late pregnant gilts, RU 486 probably affected progesterone receptor 
in the uterus and possibly glucocorticoid receptor of maternal and fetal origin 
to cause abrupt luteolysis. Such a luteolytic effect may have overridden the 
luteotropic action of PRL. 
Peak release of relaxin into the blood seems to be associated with ele­
vated PGF2^ and the termination of luteal function (Belt et al., 1971; Sher­
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wood et al., 1979, 1981; Nara and First, 1981). In pregnant gilts given RU 
486, the premature decrease in circulating progesterone concentrations was 
associated with an advanced peak relaxin release, which was beneficial to 
the induced birth process (Kertiles and Anderson, 1979; Nara et al., 1982a), 
whereas in hysterectomized gilts given RU 486, elevated progesterone con­
centrations were associated with a delayed peak relaxin release. Although 
the exact mechanism controlling the surge release of relaxin and the coinci­
dent decrease in progesterone secretion is unknown, results from this study 
reinforce the closely related secretory patterns of ovarian relaxin and proges­
terone. Decreasing production and secretion of progesterone could signal the 
release of relaxin. A nonluteolytic dose of PGF2^ (without decreasing proges­
terone secretion), however, can also cause a transient release of relaxin within 
10 min (Nara et al., 1982b). 
The dose dependent rise in circulating concentrations of RU 486 after 
oral intake of the drug in pigs was in marked contrast with that found in 
humans given similar doses of the antagonist; in humans these concentra­
tions of RU 486 ranged from 1,000 to 2,500 ng/ml and did not show any 
dose-related changes (Heihinheimo et al., 1986). The presence of a high-
affinity and low-capacity RU 486 binding protein in blood, namely a 1-acid 
glycoprotein (Moguilewsky and Philibert, 1987), may explain the divergent 
pharmacokinetic behavior of RU 486 in humans compared with that in pigs. 
The mechanism of action of RU 486 at the cellular and molecular lev­
els has not been fully elucidated. RU 486 is thought to stabilize the het-
erooligomer formed by progesterone receptor and the heat-shock protein, hsp 
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90, and thereby block the interaction between the receptor and the receptor 
binding site (hormone responsive element, HRE) on DNA (Groyer et al., 1987). 
Alternatively, the RU 486-receptor complexes may not be active because of 
a lack of appropriate conformational changes, or the complexes may bind to 
the HRE but unlike the agonist-receptor complexes are unable to promote the 
gene transactivation. 
In summary, this study in pigs with aging corpora lutea demonstrated 
divergent effects of a potent progesterone antagonist, RU 486, which depend 
upon the presence or absence of uterus (conceptuses). In pregnant animals, 
RU 486 elicited acute luteolysis, caused earlier peak relaxin release and ef­
fectively induced parturition without detrimental effects to the newborns and 
the dam. In sharp contrast with pregnant animals, the progesterone antag­
onist promoted both PRL and progesterone secretion and delayed the peak 
relaxin release in hysterectomized animals. Our in vivo results with the use 
of RU 486 suggest the involvement of an ovarian steroid, progesterone, in the 
modulation of pituitary PRL secretion and the peak release of relaxin from 
within the ovary. 
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SECTION IL INTRACEREBROVENTRICULAR ADMINISTRATION 
OF RELAXIN AND RU 486: EFFECTS ON PROLACTIN SECRETION 
IN HYSTERECTOMIZED PIGS WITH AGING CORPORA LUTEA 
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ABSTRACT 
To test whether relaxin and RU 486 exert their actions within CNS and/or 
pituitary gland to affect PRL secretion, hysterectomized pigs (hysterectomy 
performed on day 8, estrus = day 0) were subjected to cranial surgery for 
chronic placement of head mounted stereotaxic apparatus for intracerebroven-
tricular (ICV) administration of relaxin (300 Units once per day on days 111 
and 113, group 1, n = 6) and RU 486 (4 mg once per day on days 111, 113, 
and 115, group 2, n = 5). The control group (n = 3) received ICV injection of 
vehicle. In group 1, ICV injection of relaxin on day 111 markedly increased 
plasma PRL concentration from 8.2 ng/ml to 38.3 ng/ml within 10 minutes 
(P < 0.01). However, the same ICV injection of relaxin on day 113 caused 
only slight increase in PRL. The overall mean concentration of PRL after ICV 
injection of relaxin was higher than that of pretreatment values (14.1 vs 8.3 
ng/ml, P < 0.05). Plasma concentrations of relaxin and progesterone were not 
significantly affected. In group 2, ICV injection of RU 486 on day 111 greatly 
elevated plasma PRL. The increase in PRL lasted more than 2 h with several 
peak.increases of 18-29 ng/ml (P < 0.01). PRL response to subsequent ICV 
infusion of RU 486 on days 113 and 115 was blunted but the overall mean 
concentration of PRL (13.6 ng/ml) after ICV injection of RU 486 remained 
higher (P < 0.01) than pretreatment level (9.7 ng/ml). Plasma concentrations 
of relaxin and progesterone were not significantly affected in this group. In 
contrast, plasma PRL concentrations in control group remained unchanged 
after ICV injection of vehicle. These results provide strong evidence that re­
laxin exerts a central role in modulating PRL secretion in the pig. This study 
53 
reveals that RU 486 acts directly on CNS/pituitary gland to increase PRL 
secretion, suggesting a central role of progesterone. 
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INTRODUCTION 
The classic actions of relaxin are exerted on the collagenous structures 
of the cervix, the pubic symphysis, and the smooth muscle or myometrium 
of the uterus (Anderson, 1987; Sherwood, 1988). Recent evidence, however, 
has suggested a central role of relaxin, for example, in suppressing oxytocin 
secretion by the hypothalamus and neural lobe of the pituitary gland when 
applied intracerebroventricularly in the rat (Summerlee et al., 1984; Jones 
and Summerlee, 1986), and in stimulating growth hormone and PRL secre­
tion when infused intravenously in monkeys (Bethea et al., 1989). Compelling 
evidence indicates that PRL is luteotropic in the pig in promoting both pro­
gesterone and relaxin secretion, especially during later part of pregnancy and 
pseudopregnancy (i.e. after hysterectomy) (Felder et al., 1988; Anderson, 
1987; Li et al., 1989). RU 486 is a potent antagonist for progesterone recep­
tor (Baulieu, 1989). Our previous study has shown that daily administration 
of RU 486 to hysterectomized pigs from days 111-115 (estrus = day 0) causes 
a marked elevation of plasma concentrations of PRL and progesterone. There­
fore, we have developed a head mounted stereotaxic apparatus to investigate 
the effects of intracerebroventricularly applied relaxin and RU 486 on PRL 
secretion in hysterectomized pigs with aging corpora lutea. 
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MATERIALS AND METHODS 
Animals 
Purebred Yorkshire gilts (5-8 months old;=130 kg BW) with records of 
normal estrous cycles (19-21 days) were selected for this experiment. Hys­
terectomy was performed on day 8 of the estrous cycle (first day of estrus 
was designated day 0) by midventral loparotomy (Anderson et al., 1961). 
Catheterization (Tygon microbore tubing; id, 1.27 mm; od, 2.29 mm; Fisher 
Scientific, Pittsburgh, PA) of the cranial vena cava(Ford and Maurer, 1978) 
was performed on day 98 for repeated blood sample collections that began on 
day 100. 
Surgery for Mounting of Stereotaxic Apparatus 
Each gilt was fasted for 24 h before cranial surgery. On the day of surgery 
(day 109 or 110), the animals were restrained by a nasal snare and sodium 
thiamylal (0.6-1.0 g, Surital, Parke-Davis, Morris Plains, NJ) was injected i.v. 
to induce anesthesia for endotracheal intubation. The animals were placed in 
ventral recumbancy. After aseptic preparation of the surgical field, the frontal 
bone was exposed by retracting the skin flap laterally to the left side of the 
head. The superficial lamina of the frontal bone (70 x 70 mm) was removed 
using a circular bone saw (Bishop, Orthopedic Equipment Co., Bourbon, IN), 
the underlying trabeculae of the frontal sinus were removed by an osteotome, 
and the deep lamina removed by Rongeur forceps. Dura mater (20 x 20 
mm) on top of the left cerebral hemisphere was exposed and cut open with 
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spherical-tipped iris scissors at a point 5-10 mm perpendicular to the sagit­
tal midline to expose a small area (8x8 mm) of cerebrum. The stainless 
stereotaxic plate (Head Mounted Stereotaxic Apparatus, Lloyd L. Anderson 
and Leon E. Girard, inventors, ISU Research Foundation, Inc., Ames as­
signee, U. S. Patent 5,030,223, July 9, 1991) was held in place with stainless 
steel screws anchored on the frontal bone. A stainless steel guide tube (18 
gauge) with a probe needle extending a few mm beyond it was lowered from 
the stereotaxic device into cerebral cortex. The lateral ventricle was usually 
punctured at a distance of 12-18 mm below the surface of the dura. After 
the guide tube was secured on the plate, the probe needle was withdrawn 
and replaced with a stainless steel cannula connected with a fine silastic tube. 
The intracerebroventricular (ICV) cannula placement was confirmed by a) 
physiological saline in silastic tube connected to the cannula would flow freely 
in when the tubing was held above the pig's head, or b) cerebrospinal fluid 
would drip out when the end of the tubing was held below the level of the 
pig's head. The silastic tube was tunneled beneath the skin to emerge in the 
neck region and its patency was maintained by regular flushing with 0.1 ml of 
sterile physiological saline. Small pieces of gelatin sponge (Gelfoam, Upjohn 
Co., Kalamazoo, MI) soaked in thrombin (1000 units, bovine, Thrombostat, 
Parke-Davis, Morris Plains, NJ) were placed to cover the dura mater around 
the ICV cannula and powder of penicillin G (Penicillin G Potassium, Eli Lilly 
and Co., Indianapolis, IN) and streptomycin (Streptomycin Sulfate, Eli Lilly 
and Co., Indianapolis, IN) were sprinkled on the exposed surgical area, and 
finally the skin flap was sutured back to cover the stereotaxic device. During 
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surgery, about 450 ml of a 20% mannitol solution was infused i.v. to reduce 
the intracranial pressure and all exposed tissues were bathed with physiologi­
cal saline containing penicillin G (1000 units/ml) and streptomycin (1 mg/ml). 
A glass pipette was connected to a vacuum pump to aspirate the fluid from 
the surgical field. Hemorrhage was controlled by electrocoagulation and ster­
ile bone wax (Ethicon Inc., Somerville, NJ). 
Postoperative Animal Care 
Cortisone acetate (50 mg, Cortone, Merck Sharp and Dohme, Rahway, 
NJ) was given intramuscularly after surgery. Pigs were maintained in individ­
ual pens in a recovery room at 25°C. The animals were monitored intensively 
throughout the 24-h day for evidence of elevated body temperature, respira­
tion and heart beat rates and patterns of food consumption. The animals were 
assisted to resume normal food and water consumption as soon as possible; 
recovery was normal, usually within 10 h. Cortisone succinate (50 mg, Solu-
Cortef, Upjohn Co., Kalamazoo, MI) was given intravenously, as required, to 
prevent hyperthermia. 
Experimental Groups 
Pigs were randomly assigned into three groups that received ICV admin­
istration of relaxin (300 Units in 100 fd of 0.9% physiological saline, once per 
day at 1000 h on days 111 and 113; group 1, n = 6), RU 486 (4 mg in 100 
/il of ethanol, once per day at 1000 h on days 111, 113, and 115; group 2, 
n = 5), or vehicle (100 //I of 0.9% physiological saline, once per day at 1000 
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h on days 111, 113, and 115; control group, n = 3). In two treated groups, 
each ICV application of hormones was preceded an hour earlier by an ICV 
injection of vehicle (100 //I) for comparison within groups. 
Blood samples were collected once a day at 0800 h from days 100-110 
and at 5-20 minutes intervals 1 h before until 2 h after administration of 
hormones or vehicles. All blood samples (10 ml) were collected in disposable 
borosilicate culture tubes (16 x 100 mm) containing 0.2 ml heparin sodium 
salt solution (100 lU/ml; NBCO Biochemicals, Cleveland, OH) and immedi­
ately centrifuged (2000 x g) for 10 min. Plasma was decanted and stored at 
-20°C until required for PRL, relaxin, and progesterone RIAs. 
RIAs of Prolactin, Relaxin and Progesterone in Peripheral Plasma 
The PRL concentration in plasma was quantitated by double antibody 
homologous RIA, as described previously (Li et al., 1989). The radioiodination 
preparation was USDA pPRL II (potency, 103 lU/mg), and USDA pPRL B1 
(potency, 34 lU/mg) was used as the reference preparation. The sensitivity 
of the assay was 0.7 ± 0.25 ng/ml (mean ± SD; n = 5), and the inter- and 
intraassay coefficients of variation were 14 ± 3.7% (mean ± SD; 2 samples; 5 
assays) and 7.4 ± 5.5% (mean ± SD; 2 samples per assay; 2-4 determinations). 
Relaxin was quantified in duplicate 200-/zl aliquots of plasma by using a 
homologous double-antibody RIA for porcine relaxin as described previously 
(Li et al., 1989; O'Byrne and Steinetz, 1976). The sensitivity of the assay was 
40 pg/tube. The inter- and intraassay coefficients of variation were 12.4% (n 
= 3 assays/sample) and 6.2% (n = 5 samples); nonspecific binding was 2.8%. 
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Progesterone was determined in duplicate 100-/(1 aliquots of plasma ac­
cording to RIA procedures described previously (Li et al., 1989)) with the 
same fully characterized antibody (GDN-337) (Niswender, 1973; Gibori et 
al., 1977). Recovery after extraction with benzene-hexane was 89%, and the 
minimal detectable concentration of progesterone was 50 pg/tube. The inter-
and intraassay coefficients of variation were 11.3% (n = 5 assays/sample) and 
8.5% (n = 6 samples), respectively; nonspecific binding was 3.1%. 
Statistical Analyses 
Experimental units were the individual pigs, which were assigned to 
treatments at random. Data were analyzed by one way analysis of variance 
separately for samples collected each day during hormone or vehicle infusion 
and for the comparison between hormone values from the entire pretreat-
ment period and those of posttreatment period (Snedecor and Cochran 1980; 
Spector et al., 1985). 
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RESULTS 
Pigs in Control Group 
Plasma concentrations of PRL, relaxin, and progesterone are presented 
in Figure 1. From days 100-110, average PRL levels ranged from 5-15 ng/ml 
with an overall mean value of 8.8 ng/ml. Sequential sampling showed no 
changes in PRL concentrations after acute ICV infusion of vehicle on days 
111, 113, and 115. The small and transient rise in PRL on day 111 was not 
statistically significant (Figure lA). 
Relaxin concentrations increased gradually from days 100-111 and reached 
maximal levels (% 20 ng/ml) on day 113. There were no significant changes in 
relaxin concentrations on sequential samples collected intensively before and 
after ICV injection of vehicle on days 111, 113, and 115 (Figure IB) 
Progesterone concentrations remained at =25 ng/ml from days 100-113 
and started to decrease by day 115. There were no significant changes asso­
ciated with ICV injection of vehicle (Figure IC). 
. Pigs that Received ICV Injection of Relaxin 
As shown in Figure 2A, PRL concentrations in peripheral plasma av­
eraged 8.3 ng/ml from days 100-110. ICV injection of relaxin on day 111 
caused prompt and marked elevation of PRL concentrations, from a pre treat­
ment level of 8.2 ng/ml to a peak of 38.3 ng/ml within 10 minutes (P < 0.01). 
By contrast, ICV application of vehicle to the same pigs an hour prior to re­
laxin injection did not affect PRL levels. After the peak increase elicited by 
Figure 1. Concentrations of prolactin (A), relaxin (B), and progesterone (C) in peripheral plasma of pigs 
in control group (n = 3). ICV injections of vehicle (100 jil) were given on days 111, 113, and 115 
at time 0 (corresponding to 1000 h), as indicated by arrows. V^ues are means ± SE 
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relaxin, PRL concentrations decreased gradually and were maintained at 15 
ng/ml throughout day 113, which was higher than the level before relaxin 
injection (P < 0.05). However, the same ICV injection of relaxin on day 113 
only caused a slight increase in PRL that did not reach a significant level 
(Figure 2A). 
There was a gradual increase in relaxin concentrations from d&ys 100-
110. However, on days 111 and 113, relaxin did not further increase to peak 
levels as seen in the control group and there were no apparent changes in 
relaxin concentrations in response to ICV injection of relaxin (Figure 2B). 
There was a decreasing trend in progesterone concentrations from days 
100-113 (from =25 ng/ml to %15 ng/ml). ICV injection of relaxin on days 
111 and 113 did not change progesterone profiles within the sampling period 
(Figure 2C). 
Pigs that Received ICV Injection of RU 486 
PRL concentrations in peripheral plasma averaged 9.7 ng/ml before ICV 
injection from days 100-111 (Figure 3A). On day 111, ICV injection of vehicle 
did not change PRL secretion. However, ICV injection of RU 486 rapidly 
elevated PRL levels which consisted of three spike releases within a sampling 
period of 2 hours. PRL concentrations remained high on day 113 and did not 
increase in response to another ICV injection of RU 486. By day 115, PRL 
levels had fallen back to %10 ng/ml and ICV injection of RU 486 did not cause 
their further increase. The transient increase of PRL after ICV injection of 
vehicle did not reach a significant level (Figure 3A). 
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Relaxin concentrations from days 100-110 ranged from 5-10 ng/mi. The 
same levels were maintained on days 111 and 113 and there was no apparent 
response to .ICV injection of vehicle or RU 486. On day 115, relaxin levels 
increased to ^15 ng/ml but were not affected by ICV injection or vehicle of 
RU 486 during the sampling period (Figure 3B). 
Progesterone averaged 25 ng/ml from days 100-109 and decreased to 15 
ng/ml by day 110. On days 111, 113, and 115, progesterone remained at %15 
ng/ml and did not respond significantly to ICV injection of vehicle or RU 486. 
Figure 4. compares the overall plasma concentrations of PRL before and 
after ICV injection of vehicle, relaxin and RU 486. Both relaxin and RU 
486 applied intracerebroventricularly increased PRL concentrations compared 
with pretreatment levels, whereas vehicle alone was without effect. 
Figure 3. Concentrations of prolactin (A), relaxin (B), and progesterone (C) in peripheral plasma of pigs 
in RU 486-treated group (n = 5). ICV injections of RU 486 (4 mg) were given on days 111, 113, 
and 115 at time 0 (corresponding to 1000 h), as indicated by arrows. ICV injections of vehicle 
(ethanol) one hour before relaxin injections are also indicated by arrows. Values are means ± 
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Figure 4. Concentrations of prolactin in peripheral plasma of pigs before or after ICV injections of 
vehicle, relaxin, or RU 486 as so indicated. "Before" group contains all samples prior to the 
first ICV injection on day 111 and "After" group contains the rest of samples obtained. Values 
are mean ± SE. *, P < 0.05; ** P < 0.01 (compared with the values in "Before" groups) 
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DISCUSSION 
Relaxin has classically been defined as a hormone of pregnancy, with pri­
mary sites of action in the reproductive tract (Anderson, 1987; Sherwood, 
1988). More recently, the diversity in the sites of relaxin action has been 
realized through a number of experiments, both in vivo and in vitro. Relaxin 
increases cAMP levels in cultured anterior pituitary cells from rats (Cronin 
et el., 1987). This effect was not duplicated by insulin or insulin-like growth 
factor-I, which share structural homology with relaxin, and somatostatin and 
dopamine prevented the relaxin-stimulated cAMP accumulation, suggesting 
a specific effect occurring in somatotropes and lactotropes. Subsequently, re­
laxin was found to stimulate PRL secretion from cultured rat anterior pitu­
itary cells (Sortino et al., 1989). 
In this experiment, relaxin applied directly into brain ventricles induced 
a marked increase in plasma PRL on day 111, demonstrating a central stim­
ulating effect of relaxin on PRL secretion in the pig. This action of relaxin 
was specific since the ICV injection of vehicle either prior to relaxin injec-
. tion in relaxin treated group or in control group did not cause an increase 
in PRL. However, such stimulating effect of relaxin on PRL secretion de­
creased when relaxin was applied to the same pigs on day 113, This suggests 
that relaxin receptors in lactotropes of pituitary gland may have been down 
regulated by previous infusion. Similar characteristics were exhibited when 
relaxin was infused intravenously to cycling monkey (Bethea et al., 1989), in 
which low doses of relaxin (15.4 or 154 ng/kg.min) stimulated PRL secretion, 
whereas consequent infusion of relaxin to the same monkeys with high dose 
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(1540 ng/kg.min) was ineffective. Intravenous infusion of relaxin in pregnant 
monkeys also increased PRL secretion (Bethea et al., 1989). The mechanism 
by which relaxin stimulates PRL. secretion is presently unknown. Relaxin has 
been found to elevate cAMP levels in pubic symphysis (Braddon, 1978), uterus 
(Sanborn et al., 1980), and anterior pituitary (Cronin et el., 1987). However, 
whether cAMP acts as an intracellular mediator for relaxin is equivocal. PRL 
secretion is regulated by both PRL releasing factor (PRF) and PRL inhibiting 
factor (PIF). The true identity of PRF(s) and PIF(&), however, still remains 
open to debate. The principal PIF is thought to be dopamine which is secreted 
by the tuberoinfundibular dopaminergic neurons in the median eminence of 
the hypothalamus (Ben-Jonathan, 1985). A variety of substances has been 
shown to stimulate PRL secretion, these include thyrotropin releasing hor­
mone (TRH) (Van Landeghem and Van de Wiel, 1978), vasoactive intestinal 
polypeptide (VIP) (Said, 1980), /^-endorphin, substance P, and prostaglandin 
F2C^ (Leong et al., 1983; Sato et al., 1974). Estrogens are potent stimula­
tors of PRL secretion, and they are known to increase adenohypophyseal PRL 
content, pituitary gland weight, and circulating PRL concentrations in pigs 
(Anderson et al., 1972; Stevenson et al., 1981). The stimulation of relaxin 
on PRL secretion may result from its direct effect on pituitary lactotropes, or 
indirectly from its inhibition of PIFs or stimulation of PRFs in hypothalamus 
or other parts of central nervous system. 
The expected surge release of relaxin on day 113 was seen in control 
group but not in relaxin treated group. The sharp increase of PRL after ICV 
injection of relaxin on day 111 may have delayed the time for the release of 
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maximal amount of relaxin. The central action of relaxin in inhibiting oxy­
tocin release has an important physiological role. Surge releases of relaxin 
and oxytocin are precisely timed during late pregnancy and their regulation 
may be dependent on one another. Relaxin peak release at this time may 
sustain inhibition of myometrial activity during the brief period of falling pro­
gesterone and increasing estrogen secretion. The final decline in blood levels 
of relaxin could signal the neurogenic release of oxytocin in the presence of 
maximum estrogen levels to switch on intense uterine contractility for expul­
sion of the fetuses (Anderson, 1987). The physiological significance of relaxin's 
stimulation on PRL release, however, remains to be defined. 
Our previous study in hysterectomized pigs with aging corpora lutea has 
demonstrated that through its antagonistic effects on progesterone receptor, 
RU 486 promotes both PRL and progesterone secretion and delays the peak 
relaxin release. The ICV injection of RU 486 in present study provides further 
evidence that RU 486 exerts its action within CNS and/or pituitary gland to 
promote PRL secretion in hysterectomized pigs. The stimulation of PRL by RU 
486 differed from that by relaxin in that the increase in PRL on day 111 after 
ICV injection of RU,486 lasted for longer period and consisted of several spike 
releases, This may reflect the fact that RU 486 was highly hydrophobic as 
a steroid molecule. After its introduction into brain ventricles, RU 486 could 
form small deposits which released RU 486 molecules into CSF (cerebrospinal 
fluid) slowly and therefore resulted in a sustained stimulation of PRL. The PRL 
response to subsequent RU 486 injection on days 113 and 115 was blunted in 
the same fashion as that seen in relaxin treated animals, suggesting a common 
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step in the down regulation process. Similar to the results in relaxin treated 
group, there were no apparent changes in relaxin and progesterone secretion 
profiles during the intensive sampling period in response to ICV injection of 
RU 486. Higher amount of relaxin released into the plasma occurred on day 
115 as contrasted to that occurring on day 113 in the control group. High 
levels of PRL on days 111 and 113 may have inhibited the peak release of 
relaxin on day 113. 
The stimulation of PRL by ICV injection of RU 486 strongly suggest that 
progesterone produced by aging corpora lutea may act centrally to influence 
PRL secretion. Progesterone has been shown to cause depletion of the nu­
clear estrogen receptors in the anterior pituitary of the rat (Fuentes et al., 
1990). Since estrogen is a potent stimulator of PRL secretion, progesterone 
can therefore effectively oppose the action of estrogen on PRL secretion. In­
deed, progesterone inhibits PRL synthesis and blocks the stimulatory effects 
of estradiol-17/? in rat pituitary tumor cell cultures (Hang and Gautvik, 1976). 
RU 486, acting as a progesterone receptor antagonist, disinhibits the action 
of progesterone (Brann et al., 1988) and therefore causes an increase in PRL 
secretion. Administration of RU 486 also resulted in significant increases in 
serum PRL in rats and humans (Shoupe et al., 1987; Rao and Mahesh, 1986). 
In summary, the present study provides strong evidence that relaxin, à 
peptide hormone of ovarian origin, exerts a central role in modulating PRL se­
cretion in the pig. Results from this study demonstrate that RU 486, a potent 
progesterone antagonist, acts directly within CNS and /or pituitary gland to 
cause stimulation of PRL secretion, suggesting a central role of progesterone. 
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GENERAL SUMMARY 
RU 486, a potent progesterone antagonist, offers scientists a powerful tool 
for studying hormone-receptor interaction and exploring the physiological role 
of progesterone. 
In the first study, treatment with RU 486 in hysterectomized and preg­
nant pigs caused divergent effects that were dependent on the presence or 
absence of uterus (conceptuses). In pregnant animals, RU 486 elicited an 
acute luteolysis, caused earlier peak relaxin release and effectively induced 
parturition without detrimental effects to the newborns and the dam. In 
sharp contrast with pregnant animals, the progesterone antagonist promoted 
both PRL and progesterone secretion and delayed the peak relaxin release in 
hysterectomized animals. Our in uiuo results with the use of RU 486 sug­
gest the involvement of an ovarian steroid, progesterone, in the modulation of 
pituitary PRL secretion and the peak release of relaxin from within the ovary. 
Although this study has provided an insight about the role of proges­
terone in influencing relaxin and its own secretion in the pig, the factors 
which promote relaxin synthesis and storage and the mechanisms which reg­
ulate relaxin secretion, especially its prepartum peak release are still poorly 
understood. The corpus luteum seems to have intrinsic mechanisms for its 
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own regulation that we are only beginning to understand. Because it is an 
ephemeral gland, the corpus luteum has unusual requirements in that it must 
prepare for its own destruction while fulfilling its crucial role of progesterone 
and relaxin secretion. The peak release of relaxin and coincident decrease in 
progesterone secretion on about day 113 in both pregnant and hysterectomized 
pigs may be a preprogrammed event related to the aging of porcine corpora 
lutea whose life-span are defined through evolutionary development of the re­
productive cycle as the duration of gestation of about 114 days. The challenge 
for the future is to discover those intracellular and intercellular events that 
allow the corpus luteum to play out this scenario. By taking advantage of the 
availability of RU 486, one could study the effect of intraluteal implant of this 
potent progesterone antagonist on luteal function and pituitary hormone se­
cretions. The effect of RU 486 treatment on mRNA levels of relaxin detected 
by in situ hybridization in the ovary would generate information regarding 
the synthesis of relaxin. Furthermore, it would be interesting to look at the 
effect of RU 486, alone br in combination with other factors on the function 
of dispersed luteal cells in priniary culture. 
The development of a stereotaxic device for ICV infusion and the related 
cranial surgical techniques have allowed us to elucidate the site of hormorte 
action within CNS/pituitary gland of the pig. The second study presented in 
this dissertation provide strong evidence that relaxin, a peptide hormone of 
ovarian origin, exerts a central role in modulating PRL secretion in the pig. 
Results clearly demonstrate that RU 486, a potent progesterone antagonist, 
acts directly within CNS and/or pituitary gland to cause stimulation of PRL 
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secretion, suggesting a central role of progesterone. 
To provide better understanding of the central role of relaxin, future ex­
periment could be conducted to study the effects of ICV infusion of different 
doses of relaxin on the secretion of PRL, GH, gonadotropins, and oxytocin in 
hysterectomized, pregnant, and lactating pigs. It would be also of interest to 
study the effects of relaxin, progesterone, and RU 486 on the secretory func­
tion of cultured pituitary cells from pigs at different stages of pregnancy and 
after hysterectomy. 
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APPENDIX A. 
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Table Al. RU 486 in peripheral plasma of pregnant gilts (ng/ml, mean ± SE) 
Days after Before Placebo RU486 
mating Hours treatment (n=ll) control  ^(n=5) groupé (n=6) 
100 0800 0.10 ±0.01 
101 0800 0.10 + 0.01 
102 0800 0.10 ±0.01 
103 0800 0.10 ±0.01 
104 0800 0.10 ±0.01 
105 0800 0.10 ±0.01 
106 0800 0.10 ±0.01 
107 0800 0.10 ±0.01 
108 0800 0.10 ±0.01 
109 0800 0.10 ±0.01 
110 0800 0.10 ±0.01 
111 0600 0.10 ±0.01 0.10 ± 0.01 
111 1200 0.10 ±0.01 77.41 ± 9.28 
111 1800 0.10 ±0.01 57.05 ± 6.84 
111 2400 0.10 ±0.01 47.16 ± 5.65 
112 0600 0.10 ±0.01 27.96 ± 3.35 
112 1200 d.io±o.oi 36.82 i 4.41 
112 1800 0.10 ±0.01 54.67 ± 6.56 
m 2400 0.10 ±0.01 51.55 ± 6.18 
113 0800 0.10 ±0.01 41.92 ± 5.03 
114 0800 0.10 ±0.01 18.84 ± 2.26 
115 0800 0.10 ±0.01 10.10 ± 1.21 
116 0800 0.10 ±0.01 4.76 ± 0.57 
117 0800 0.10 ±0.01 4.00 ± 0.48 
118 0800 0.10 ±0.01 1.60 ± 0.19 
119 0800 0.10 ±0.01 1.50 ± 0.18 
120 0800 0.10 ±0.01 1.00 ± 0.12 
 ^RU 486 at a dosage of 4 mg/kg BW was given orally at 0800 h on 
days 111 and 112 after mating. The controls were given the same amount of 
feed without the drug at those times. 
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Table A2. Progesterone in peripheral plasma of pregnant gilts (ng/ml, mean 
±SE) 
Days after Before Placebo RU 486 
mating treatment (n=ll) control  ^(n=5) groupé (n=6) 
100 10.02 ±0.64 
101 10.18 ±0.54 
102 10.91 ±0.71 
103 10.85 ±0.99 
104 11.97 ±0.58 
105 11.65 ±0.90 
106 12.45 ±1.12 
107 10.78 ±1.07 
108 11.11 ±1.18 
109 11.35 ±1.00 
110 10.13 ±0.70 
111 9.52 ±0.81 9.63 ±0.97 
112 9.24 ±1.59 2.52 ±1.13 
113 5.62 ±1.32 0.50 ±0.10 
114 2.08 ±0.57 0.57 ±0.12 
115 0.65 ±0.19 0.48 ±0.11 
116 0.45 ±0.06 0.44 ±0.09 
117 0.42 ±0.05 0.40 ±0.06 
118 0.39 ±0.04 0.39 ±0.04 
119 0.35 ±0.01 0.41 ±0.06 
120 0.36 ±0.01 0.37 + 0.02 
 ^RU 486 at a dosage of 4 mg/kg BW was given orally at 0800 h on 
days 111 and 112 after mating. The controls were given the same 
amomit of feed without the drug at those times. 
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Table A3. Relaxin in peripheral plasma of pregnant gilts (ng/ml, mean ± SE) 
Days after Before Placebo RU 486 
mating Hours treatment (n=ll) control^ (n=5) groupé (n=6) 
100 0800 2.10 ±  0.21 
101 0800 2.40 ±  0.26 
102 0800 . 2.23 ±  0.31 
103 0800 3.42 ±  0.41 
104 0800 3.62 ±  0.43 
105 0800 4.60 ±  0.55 
106 0800 5.02 ± '  0.60 
107 0800 5.64 ±  0.67 
108 0800 5.52 + 0.66 
109 0800 13.74 ±  1.64 
110 0800 15.30 ±  1.83 
111 0600 27.63 ±  3.31 16.05 ±  1.92 
111 1200 20.74 ± 2.48 22.70 ±  2.72 
111 1800 19.64 ± 2.35 27.12 ±  3.25 
111 2400 26.57 ±  3.18 88.52 ±  10.62 
112 0600 27.63 ±  3.31 116.0 ± 16.24 
112 1200 . 28.91 ±  3.46 58.72 ±  7.04 
112 1800 29.48 ±  3.53 41.60 ±  4.99 
112 2400 42.66 ±  5.11 27.32 ±  3.27 
113 0600 38.16 ±  4.57 29.22 ±  3.51 
113 1200 51.82 ± 6.21 9.06 ±  1.08 
113 1800 55.82 ±  6.68 3.62 ±  0.43 
113 2400 66.51 ±  7.98 2.66 ±  0.31 
114 0600 72.69 ±  7.02 1.50 ±  0.18 
114 1200 51.60 ±  6.18 1.21 ±  0.13 
114 1800 25.02 ±  3.02 0.77 ±  0-.09 
114 2400 27.00 ±  3.24 0.64 ±  0.07 
115 0600 29.34 ± 3.52 0.40 ±  0:04 
115 1200 18.40 ±  2.20 0.36 ±  0.03 
115 1800 , 7.73 ±  0.92 0.34 ±  0.02 
115 2400 4.65 ±  0.55 0.30 ±  0.03 
116 0600 2.33 ±  0.27 0.32 ±  0.02 
116 1200 3.15 ±  0.37 0.33 ±  0.03 
116 1800 2.30 ±  0.27 0.34 ±  0.03 
116 2400 0.77 ±  0.08 0.31 ±  0.Ô2 
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Table A3, (continued) 
Days after Before Placebo RU 486 
mating Hours treatment (n=ll) control^ (n=5) groupé (n=6) 
117 
118 
119 
120 
0800 
0800 
0800 
0800 
0.64 ± 0.07 
0.46 ± 0.03 
0.38 ± 0.04 
0.35 ± 0.03 
0.32 ± 0.03 
0.30 ± 0.02 
0.33 ± 0.03 
0.30 ± 0.02 
 ^RU 486 at a dosage of 4 mg/kg BW was given orally at 0800 h on 
days 111 and 112 after mating. The controls were given the same amount 
of feed without the drug at those times. 
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Table A4. Prolactin, in peripheral plasma of pregnant gilts (ng/ml, mean ± SE) 
Days after Before Placebo RU 486 
mating Hours treatment (n=ll) control^ (n=5) groupé (n=6) 
100 0800 9.86 ±  1.18 
101 0800 10.25 ±  1.23 
102 0800 8.92 ± 1.06 
103 0800 8.25 ± 1.02 
104 0800 7.52 ±  0,92 
105 0800 10.94 ±  1.31 
106 0800 9.52 ±  1.14 
107 0800 13.20 ±  1.58 
108 0800 12.40 ±  1.48 
109 0800 21.40 ±  2.56 
110 0800 20.05 ±  2.42 
111 0600 35.42 .  ±  4.24 28.62 ±  2.84 
111 1200 32.74 ±  3.84 28.42 ±  2.62 
111 1800 28.02 ±  2.96 28.90 ±  2.94 
111 2400 43.30 ±  4.46 37.44 + 3.84 
112 0600 46.62 ±  4.81 38.20 ±  3.56 
112 1200 31.04 ±  3.26 54.82 ±  5.26 
112 1800 28.62 ±  2.95 69.22 ±  6.24 
112 2400 41.32 ±  4.23 88.22 ±  8.02 
113 0600 43.62 ±  4.02 38.35 ±  3.89 
113 1200 40.02 ±  4.26 46.04 ±  4.93 
113 1800 42.20 ±- 3.89 44.62 ±  4.75 
113 2400 48.40 ±  4.24 41.24 ±  3.88 
114 0600 . 54.52 ±  4.59 31.40 ± 3.54 
114 1200 73.72 ±  7.96 33.32 ±  3.84 
114 1800 51.80 •± 5.46 39.02 ±  3.22 
114 2400 60.25 ±  6.87 32.55 ±  3.52 
115 0600 73.76 ±  6.89 32.02 ±  3.56 
115 1200 64.20 ±  6.81 29.12 ±  2.52 
115 1800 72.61 ±  7.03 28.32 ±  3.02 
115 2400 59.02 ±  6.02 29.02 ±  3.12 
116 0600 50.01 ±  5.74 30.80 ±  3.28 
116 1200 47.50 ±  4.96 37.82 ±  3.54 
116 1800 51.82 ±  5.41 29.21 ±  3.02 
116 2400 30.32 ±  3.47 33.02 ±  3.21 
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Table A4, (continued) 
Days after Before Placebo RU 486 
mating Hours treatment (n=ll) control  ^(n=5) groupé (n=6) 
117 0800 22.77 ± 2.31 20.62 ± 2.06 
118 0800 13.02 ± 1.42 25.40 ± 2.46 
119 0800 18.02 ± 1.59 30.62 ± 3.23 
120 0800 17.20 ± 1.54 25.70 ± 2.87 
^ RU 486 at a dosage of 4 mg/kg BW was given orally at 0800 h on 
days 111 and 112 after mating. The controls were given the same amount 
of feed without the drug at those times. 
Table A5. RU 486 in peripheral plasma of hysterectomized gilts (ng/ml, mean ± SE) 
Days after Before Placebo RU 486 RU 486 
estrus Hours treatment (n=18) control  ^(n=6) group (n=5) group 2  ^(n=7) 
100 oaoo 
101 0800 
102 0800 
103 0800 
104 0800 
105 0800 
106 0800 
107 0800 
108 0800 
109 0800 
110 0800 
111 0600 
111 1200 
111 1800 
111 2400 
112 0600 
112 1200 
112 1800 
112 2400 
113 0600 
113 1200 
0.10 ±0.01 
0.10 ±0.01 
o.io±o.oi 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 
0.10 ±0.01 0.10 ± 0.01 0.10 ± 0.01 
0.10 ±0.01 18.04 ± 1.56 55.08 ± 5.12 
0.10 ±0.01 19.82 ± 2.01 65.44 ± 5.86 
0.10 ±0.01 15.28 ± 1.48 29.02 ± 3.02 
0.10 ±0.01 8.22 ± 0.79 26.84 ± 2.14 
0.10 ±0.01 20.24 ± 2.01 104.2 ± 9.56 
0.10 ±0.01 23.06 ± 2.17 88.26 ± 7.59 
0.10 ±0.01 17.01 ± 1.87 81.31 ± 7.89 
0.10 ±0.01 14.87 ± 1.39 52.89 ± 6.02 
0.10 ±0.01 34.15 ± 3.17 94.76 ± 8.13 
Table A5. (continued) 
Days after Before Placebo RU486 RU486 
estrus Hours treatment (n=18) control  ^(n=6) group 1  ^(n=5) group 2  ^(n=7) 
113 1800 0.10 ±0.01 21.38 ± 2.31 104.9 ± 9.47 
113 2400 0.10 ±0.01 21.05 ± 1.98 86.10 ± 7.28 
114 0600 0.10 ±0.01 15.62 ± 1.48 66.94 ± 5.49 
114 1200 0.10 ±0.01 39.70 ± 4.17 110.0 ± 10.24 
114 1800 0.10 ±0.01 27.24 ± 2.46 95.01 ± 8.27 
114 2400 0.10 ±0.01 21.07 ± 2.09 78.13 ± 7.98 
115 0600 0.10 ±0.01 14.45 ± 1.57 60.59 ± 5.79 
115 1200 0.10 ±0.01 43.97 ± 4.23 104.4 ±' 8.46 
115 1800 0.10 ±0.01 28.09 ± 2.87 89.91 ± 8.47 
115 2400 0.10 ±0.01 24.35 ± 2.48 80.87 ± 8.19 
116 0600 0.10 ±0.01 13.28 ± 1.25 72.09 ± 7.49 
116 1200 0.10 ±0.01 11.62 ± 1.07 65.23 ± 5.89 
116 1800 0.10 ±0.01 10.52 ± 1.05 54.91 ± 5.97 
116 2400 0.10 ±0.01 10.93 ± 1.01 47.06 ± 4.19 
117 0800 0.10 ±0.01 6.88 ± 0.76 28.37 ± 2.47 
118 0800 0.10 ±0.01 4.20 ± 0.38 17.76 ± 1.49 
119 0800 0.10 ±0.01 2.38 ± 0.31 13.69 ± 1.28 
120 0800 0.10 ±0.01 1.86 ± 0.21 8.31 ± 0.91 
® RU 486 at a dosage of 2 mg/kg BW (group 1) or 4 mg/kg BW (group 2) was given 
orally at 0800 h on days 111-115 after estrus. The controls were given the same amount of 
feed without the drug at those times. 
Table A6. Progesterone in peripheral plasma of hysterectomized gilts (ng/ml, mean ± SE) 
Days after Before Placebo RU 486 RU 486 
estrus treatment (n=18) control  ^(n=6) group 1  ^(n=5) group 2  ^(n=7) 
100 28.2012.17 
101 29.41 ±2.20 
102 28.97 ±2.76 
103 25.15 ±1.82 
104 26.43 ±1.89 
105 30.35 ±2.31 
106 27.97 ±2.00 
107 27.45 ±2.31 
108 27.56 ±2.13 
109 26.62 ±2.17 
110 26.47 ±1.62 
111 22.04 ±1.90 31.19 ± 2.94 30.81 ±3.32 
112 22.66 ± 2.26 28.57 ± 3.14 33.84 ±2.01 
113 20.55 ±1.35 30.98 ±1.98 39.37 ±3.96 
114 21.44 ± 2.54 33.27 ±1.84 41.38 ±4.07 
115 22.59 ±2.58 33.68 ± 3.36 42.30 ±4.55 
116 22.81 ±2.52 29.24 ±1.29 36.33 ±2.90 
117 21.74 ±3.55 30.38 ±1.24 35.93 ±4.14 
118 22.49 ± 3.70 26.99 ±3.53 31.12 ±3.04 
119 22.25 ± 3.95 24.16 ±1.87 27.52 ±4.31 
120 22.57 ± 2.89 25.36 ±2.10 30.69 ±4.51 
 ^RU 486 at a dosage of 2 mg/kg BW (group 1) or 4 mg/kg BW (group 2) was given 
orally at 0800 h on days 111-115 after estrus. The controls were given the same amount 
of feed without the drug at &ose times. 
100 
101 
102 
103 
m 
105 
106 
107 
108 
109 
110 
111 
111 
111 
111 
112 
112 
112 
112 
113 
Relaxin in peripheral plasma of hysterectomized gilts (ng/ml, mean ± SE) 
Hours 
Before Placebo 
treatment (n=18) control  ^(n=6) 
RU486 
group 1  ^(n=5) 
RU486 
group 2  ^(n=7) 
0800 
0800 
0800 
0800 
0800 
0800 
0800 
0800 
0800 
0800 
0800 
4.52 ±0.39 
4.90 ±0.47 
5.04 ±0.52 
4.81 ±0.48 
5.02 ±0.49 
5.10 ±0.52 
5.41 ±0.38 
5.92 ±0.58 
6.02 ±0.69 
6.70 ±0.73 
7.10 ±0.65 
0600 7.04 ± 0.81 8.08 ± 0.84 7.10 ± 0.71 
1200 7.62 ± 0.59 7.53 ± 0.73 6.31 ± 0.64 
1800 7.34 ± 0.74 7.04 ± 0.76 6.82 ± 0.62 
2400 9.27 ± 0.79 6.51 ± 0.63 6.82 ± 0.71 
0600 8.70 ± 0.78 7.54 ± 0.73 7.03 ± 0.98 
1200 8.01 ± 0.91 6.84 ± 0.71 6.51 ± 0.73 
1800 8.08 ± 0.81 6.08 ± 0.68 6.81 ± 0.76 
2400 9.02 ± 0.93 6.20 ± 0.62 8.06 ± 0.84 
0600 9.32 ± 0.93 8.04 ± 0.95 7.52 ± 0.79 
1200 11.51 ± 1.08 6.92 ± 0.61 7.21 ± 0.81 
Table A7. (continued) 
Days after Before Placebo RU 486 EU 486 
estrus Hours treatment (n=18) control  ^(n=6) group 1  ^(n=5) group 2  ^(n=7) 
113 1800 11.01 ± 1.03 6.83 ± 0.69 8.74 ± 0.84 
113 2400 13.02 ± 1.35 7.23 ± 0.64 9.03 ± 0.91 
114 0600 18.70 ± 2.50 7.84 ± 0.75 8.03 ± 0.86 
114 1200 8.71 ± 0.84 6.22 ± 0.63 8.51 ± 0.84 
114 1800 10.40 ± 1.32 8.01 ± 0.81 7.66 ± 0.72 
114 2400 10.02 ± 0.93 8.58 ± 0.74 8.21 ± 0.69 
115 0600 11.01 ± 1.03 8.21 ± 0.84 9.07 ± 0.84 
115 1200 9.22 ± 0.91 8.20 ± 0.71 7.03 ± 0.62 
115 1800 8.67 ± 0.81 8.51 ± 0.85 8.06 ± 0.93 
115 2400 10.07 ± 0.99 8.84 ± 0.68 9.80 ± 0.87 
116 0600 11.40 ± 0.93 13.22 ± 1.30 9.05 ± 0.84 
116 1200 10.02 ± 1.02 8.13 ± 0.78 8.87 ± 0.91 
116 1800 9.24 ± 0.86 8.01 ± 0.78 9.07 ± 0.88 
116 2400 8.96 ± 0.89 7.51 ± 0.77 8.62 ± 0.74 
117 0800 9.70 ± 0.84 9.00 ± 0.49 16.29 ± 1.90 
118 0800 8.02 ± 0.86 7.84 ± 0.69 8.56 ± 0.84 
119 0800 9.02 ± 0.93 7.51 ± 0.62 9.02 ± 0.93 
120 0800 8.40 ± 0.74 6.50 ± 0.52 6.83 ± 0.63 
 ^RU 486 at a dosage of 2 mg/kg BW (group 1) or 4 mg/kg BW (group 2) was given 
orally at 0800 h on days 111-115 after estrus. The controls were given the same amount of 
feed without the drug at those times. 
Table A8. Prolactin in peripheral plasma of hysterectomized gilts (ng/ml, mean ± SE) 
Days after Before 
estrus treatment (n=18) 
Placebo 
control  ^(n=6) 
RU486 RU486 
group 1  ^(n=5) group 2  ^(n=7) 
100 3.05 ±0.35 
101 3.44 ±0.64 
102 3.26 ±0.61 
103 3.33 ±0.66 
104 3.57 ±0.67 
105 3.19 ±0.64 
106 3.52 ±0.55 
107 3.66 ±0.67 
108 3.29 ±0.50 
109 3.33 ±0.59 
110 3.53 ±0.53 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
3.43 ± 1.02 8.34 ± 2.44 6.37 ± 1.50 
3.14 ± 0.65 10.04 ± 0.82 11.77 ± 2.34 
2.87 ± 0.71 10.07 ± 1.97 11.56 ± 1.95 
3.39 ± 1.09 9.08 ± 1.58 9.28 ± 2.10 
3.97 ± 1.11 7.37 ± 0.94 7.05 ± 1.40 
3.09 ± 0.83 6.68 ± 1.36 5.72 ± 1.00 
2.64 ± 0.85 4.23 ± 1.16 7.14 ± 2.58 
2.97 ± 0.74 3.08 ± 1.45 8.42 ± 3.62 
3.31 ± 1.32 2.89 ± 0.86 8.57 ± 3.26 
3.79 ± 1.18 3.65 ± 1.08 4.43 ± 1.14 
 ^RU 486 at a dosage of 2 mg/kg BW (group 1) or 4 mg/kg BW (group 2) was given 
orally at 0800 h on days 111-115 after estrus. The controls were given the same amount 
of feed without the drug at those times. 
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Table A9. Prolactin in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricular) injection of 
vehicle (n=3) 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 11.07 ± 1.04 
101 3.91 ± 0.28 
102 5.05 ± 0.62 
103 14.20 ± 1.14 
104 8.93 ± 0.68 
105 5.02 ± 0.54 
106 7.37 ± 0.78 
107 4.35 ± 0.41 
108 6.92 ± 0.57 
109 9.32 ± 0.87 
110 9.46 ± 0.88 
111 -60 8.28 ± 0.79 
111 •40 9.15 ± 0.91 
111 -20 6.82 ± 0.75 
111 0 7.22 ± 0.81 
111 5 9.06 ± 0.87 
111 , 10 9.83 ± 0.83 
111 15 18.54 ± 1.45 
111 20 10.23 ± 1.04 
111 40 7.72 ± 0.79 
111 00 8.39 ± 0.95 
111 80 4.57 ± 0.36 
111 . 1 0 0  6.95 ± 0.68 
111 120 15.03 ± 1.46 
113 -60 7.81 ± 0.67 
113 •40 6.38 ± 0.69 
113 -20 7.67 ± 0.74 
113 0 7.08 ± 0.58 
113 5 6.39 ± 0.77 
113 10 9.69 ± 0.86 
113 15 8.41 ± 0:72 
113 20 8.04 ± 0.95 
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Table A9. (continued) 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 40 5.70 ± 0.51 
113 60 5.29 ± 0.49 
113 80 6.73 •± 0.64 
113 100 6.11 ± 0.54 
113 120 4.52 ± 0.39 
115 -60 3.78 ± 0.41 
115 -40 2.82 ± 0.31 
115 -20 3.47 ± 0.34 
115 0 7.88 ± 0.65 
115 5 7.71 ± 0.71 
115 10 4.03 ± 0.52 
115 . 15 7.50 ± 0.63 
115 20 3.55 ± 0.33 
115 40 4.92 ± 0.39 
115 60 3.57 ± 0.37 
115 80 3.54 ± 0.41 
115 100 4.11 ± 0.41 
115 120 5.04 ± 0.49 
^ ICV injections of vehicle (100 |il) were given on days 111, 
113, and 115 after the blood sample collection at time 0 
(corresponding to 1000 h). 
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Table AlO. Relaxin in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricular) injection of 
vehicle (n=3) 
Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 7.74 ± 0.71 
101 9.71 ± 0.84 
102 7.79 ± 0.65 
103 7.52 ± 0.59 
104 7.79 ± 0.81 
105 7.70 ± 0.77 
106 6.61 ± 0.54 
107 9.78 ± 0.82 
108 12.54 ± 1.11 
109 8.99 ± 0.77 
110 15.06 ± 1.18 
111 -60 12.42 ± 1.17 
111 40 14.27 ± 1.26 
111 -20 15.62 ± 1.56 
111 0 17.62 ± 1.52 
111 5 17.05 ± 1.19 
111 . 10 17.12 ± 1.71 
111 15 16.73 ± 1.69 
111 20 15.00 ± 1.47 
111 40 13.70 ± 1.34 
111 60 11.77 ± 1.24 
111 80 11.38 ± 1.46 
111 . 1 0 0  9.49 ± 0.84 
111 120 ,9.69 ± 0.91 
113 -60 18.61 ± 1.88 
113 -40 19.29 ± 1.54 
113 -20 16.24 ± 1.62 
113 0 20.60 ± 1.94 
113 5 19.10 ± 1.58 
113 10 18.37 ± 1.54 
113 15 19.47 ± 2.04 
113 20 20.32 ± 1.57 
109 
Table AlO. (continued) 
Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 40 17.43 ± 1.24 
113 60 12.57 ± 1.19 
113 80 16.19 + 1.57 
113 100 15.06 ± 1.10 
113 120 14.84 ± 1.48 
115 -60 10.58 ± 1.17 
115 -40 11.25 ± 1.47 
115 -20 15.24 ± 1.21 
115 0 13.85 ± 1.26 
115 5 13.53 ± 1.35 
115 10 13.17 ± 1.04 
115 15 12.81 ± 1.15 
115 20 12.53 ± 1.46 
115 40 11.17 ± 0.97 
115 60 10.81 ± 1.14 
115 80 11.49 ± 1.41 
115 100 11.34 ± 1.12 
115 120 10.84 ± 1.03 
^ ICV injections of vehicle (100 |il) were given on days 111, 
113, and 115 after thé blood sample collection at time 0 
(corresponding to 1000 h). 
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Table All. Progesterone in peripheral plasma of hysterectomized 
gilts received ICV (intracerebroventricular) injection of 
vehicle (n=3) 
Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 
101 
102 
103 
104 
105 
106 
107 
108 
109 
110 
111 -60 17.31 ± 1.25 
111 -40 17.89 ± 1.04 
111 • -20 19.18 ± 1.89 
111 0 21.89 ± 2.01 
111 5 18.40 ± 1.07 
111 10 18.52 ± 1.24 
111 15 18.41 ± 1.54 
111 20 26.81 ± 2.49 
111 40 24.04 ± 2.47 
111 .60 24.96 ± 1.48 
111 80 23.07 ± 1.33 
111 100 22.77 ± 2.11 
111 120 24.70 ± 2.13 
113 -60 25.96 ± , 1.24 
113 -40 25.49 ± 2.51 
113 -20 28.88 ± 2.46 
113 0 26.42 ± 1.99 
113 5 24.44 ± 2.07 
113 10 26.46 ± 1.46 
113 15 25.34 ± 2.36 
113 20 23.21 ± 1.89 
24.85 ± 1.87 
29.39 ± 2.39 
24.01 ± 2.01 
22.04 ± 2.38 
23.73 ± 1.02 
26.08 ± 2.14 
28.83 ± 2.89 
26.40 ± 2.64 
24.99 ± 1.15 
28.21 ± 1.99 
24.24 ± 2.09 
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Table All. (continued) 
Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 40 24.18 ± 2.01 
113 GO 24.34 ± 1.25 
113 80 27.30 ± 2.47 
113 100 32.24 ± 3.59 
113 120 33.80 ± 3.47 
115 -60 28.39 ± 2.14 
115 -40 30.85 ± 3.07 
115 -20 28.54 ± 2.31 
115 0 26.60 ± 2.34 
115 5 29.91 ± 1.44 
115 10 26.18 ± 2.58 
115 15 23.42 ± 2.42 
115 20 16.29 ± 1.21 
115 40 25.41 ± 1.88 
115 60 23.40 ± 2.11 
115 80 21.96 ± 1.11 
115 100 23.99 ± 2.33 
115 120 23.80 ± 1.46 
^ ICV injections of vehicle (100 |il) were given on days 111, 
113, and 115 after the blood sample collection at time 0 
(corresponding to 1000 h). 
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Table A12. Prolactin in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventrictxlar) injection of 
relaxin (n=6) 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 11.24 ± 0.94 
101 13.25 + 1.07 
102 7.70 ± 0.71 
103 7.51 ± 0.81 
104 7.82 ± 0.73 
105 6.17 ± 0.58 
106 6.34 ± 0.61 
107 6.38 ± 0.59 
108 8.48 ± 0.95 
109 8.32 ± 0.74 
110 8.25 ± 0.92 
111 -120 7.51 ± 0.62 
111 -100 7.00 ± 0.81 
111 -80 7.57 ± 0.74 
111 -60 9.28 ± 0.87 
111 -55 8.18 ± 0.71 
111 -50 7.70 ± 0.86 
111 -45 6.20 ± 0.59 
111 -40 7.20 ± 0.71 
111 -20 7.10 + 0.79 
111 0 8.17 ± 0.87 
111 5 19.37 ± 1.21 
111 , 10 38.26 ± 4.02 
111 15 22.32 i 2.34 
111 20 22.11 ± 2.23 
111 40 14.31 ± 1.05 
111 60 11.98 ± 2.08 
111 80 11.94 ± 1.07 
111 100 12.13 ± 1.27 
111 120 11.49 ± 1.13 
113 -120 12.06 ± 1.10 
113 -100 13.40 ± 1.17 
Table A12. (continued) 
113 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 -80 12.30 ± 1.11 
113 -60 10.95 ± 0.96 
113 -55 11.49 ± 1.27 
113 -50 10.65 ± 0.97 
113 -45 13.32 ± 1.44 
113 -40 10.77 ± 0.85 
113 -20 14.00 ± 1.08 
113 0 14.50 ± 1.26 
113 5 12.92 ± 1.13 
113 10 14.57 ± 1.49 
113 15 19.83 ± 1.47 
113 20 13.66 + 1.28 
113 40 13.20 ± 1.17 
113 60 11.46 + 0.99 
113 80 10.24 ± 1.02 
113 100 13.09 ± 1.11 
113 120 9.60 ± 0.56 
 ^ICV injections of rèlaxin (300 units ) were given on days 111 
and 113 after the blood sample collection at time 0 (corresponding to 
1000 h). One hour prior to relaxin injections, all gilts received ICV 
injections of vehicle (100 |J,1) at time -60 minutes (corresponding to 
0900 h) .  
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Table A13. Relaxin in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricular) injection of 
relaxin (n=6) 
Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 5.90 ± 0.35 
101 6.66 ± 0.58 
102 5.54 ± 0.41 
103 8.57 ± 0.49 
104 8.00 ± 0.71 
105 6.54 ± 0.36 
106 8.16 ± 0.67 
107 11.78 ± 0.94 
108 14.24 ± 0.11 
109 12.80 ± 0.97 
110 10.21 ± 0.85 
111 -120 3.46 ± 0.21 
111 -100 3.80 ± 0.29 
111 -80 4.02 ± 0.33 
111 -60 4.31 + 0.41 
111 -55 4.03 ± 0.39 
111 -50 3.62 ± 0.18 
111 -45 3.81 ± 0.37 
111 -iO 3.62 ± 0.36 
111 -20 3.70 ± 0.28 
111 0 3.71 ± 0.25 
111 5 4.48 ± 0.35 
111 10 4.30 ± 0.43 
111 15 5.14 ± 0.41 
111 20 4.93 ± 0.34 
111 40 7.52 ± 0.63 
111 60 7.05 .+ 0.64 
111 80 6.94 ± 0.56 
111 100 7.36 ± 0.59 
111 • 120 6.50 ± 0.52 
113 
113 
-120 8.88 ± 0.74 
-100 9.20 ± 0.87 
Table A13. (continued) 
115 
Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 -80 9.41 ± 0.57 
113 -60 10.10 ± 0.92 
113 -55 9.98 ± 0.78 
113 -50 8.62 ± 0.81 
113 -45 8.43 ± 0.59 
113 -40 8.00 ± 0.91 
113 -20 7.26 ± 0.71 
113 0 7.01 ± 0.64 
113 5 7.79 ± 0.83 
113 10 8.36 ± 0.84 
113 15 9.49 ± 0.94 
113 20 8.88 ± 0.74 
113 40 8.21 ± 0.83 
113 60 7.86 ± 0.49 
113 80 7.45 ± 0.61 
113 100 7.70 ± 0.29 
113 120 7.81 ± 0.86 
 ^ICV injections of relaxin (300 units ) were given on days 111 
and 113 after tiie blood sample collection at time 0 (corresponding to 
1000 h). One hour prior to relaxin injections, all gilts received ICV 
injections of vehicle (100 |il) at time -60 minutes (corresponding to 
0900 h) .  
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Table A14. Progesterone in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricular) injection of 
relaxin 
(n=6) 
Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 30.18 ± 2.98 
101 32.17 ± 3.14 
102 27.06 ± 1.83 
103 25.34 ± 3.16 
104 24.16 ± 1.47 
105 23.82 ± 2.01 
106 22.50 ± 1.46 
107 21.87 ± 1.79 
108 23.10 ± 1.54 
109 20.72 ± 1.79 
110 19.40 ± 1.21 
111 -120 14.87 ± 1.02 
111 -100 15.50 ± 1.27 
111 -80 17.07 ± 1.47 
111 -60 16.10 ± 1.49 
111 -55 15.80 ± 1.53 
111 -50 22.34 ± 1.89 
111 -45 15.24 ± 1.57 
111 -40 14.85 ± 1.39 
111 -20 17.36 ± 1.27 
111 0 14.89 ± 1.47 
111 5 15.24 + • 1.33 
111 10 15.81 ± 0.97 
111 15 15.50 ± 1.11 
111 20 16.09 ± 1.08 
111 40 16.00 ± 1.02 
111 60 15.19 ± 0.79 
111 80 15.91 ± 1.01 
111 100 15.17 ± 0.93 
111 120 14.46 ± 1.07 
113 -120 18.25 ± 0.91 
113 -100 20.57 ± 1.76 
Table A14. (continued) 
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Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 -80 17.40 ± 1.07 
113 -60 13.87 ± 1.13 
113 -55 12.85 ± 0.95 
113 -50 14.91 ± 1.01 
113 -45 14.53 ± 1.33 
113 -40 16.21 ± 0.99 
113 -20 15.78 ± 1.07 
113 0 15.69 ± 0.79 
113 5 17.23 .± 0.88 
113 10 17.15 ± 1.03 
113 15 17.18 ± 1.14 
113 20 16.25 ± 1.09 
113 40 14.99 ± 1.16 
113 60 15.51 ± 0.86 
113 80 16.50 ± 1.21 
113 100 16.33 ± 0.82 
113 120 15.27 ± 1.04 
 ^ICV injections of relaxin (300 units ) were given on days 111 
and 113 after the blood sample collection at time 0 (corresponding to 
1000 h). One hour prior to relaxin injections, all gilts received ICV 
injections of vehicle (100 |il) at time -60 minutes (corresponding to 
0900 h) .  
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Table A15. Prolactin in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricvdar) injection of RU 
486 (n=5) 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 12.44 ± 1.04 
101 7.06 ± 0.78 
102 5.11 ± 0.47 
103 5.10 ± 0.58 
104 6.03 ± 0.49 
105 5.70 ± 0.42 
106 6.47 ± 0.56 
107 7.00 ± 0.71 
108 6.13 ± 0.53 
109 6.93 + 0.62 
110 8.88 ± 0.46 
111 -120 7.45 ± 0.59 
111 -100 7.61 ± 0.51 
111 -80 9.67 ± 0.84 
111 -60 9.24 ± 0.61 
111 -55 5.69 ± 0.43 
111 -50 9.39 ± 0.74 
111 -45 10.28 ± 0.92 
111 -40 11.54 ± 1.01 
111 -20 13.33 ± 1.09 
111 0 12.34 ± 1.21 
111 5 20.58 ± 2.68 
111 10 20.68 ± 2.04 
111 15 26.16 ± 1.96 
111 20 29.57 ± 2.07 
111 40 15.96 i 1.03 
111 60 26.08 ± 2.06 
111 80 16.86 ± 1.57 
111 100 11.31 ± 1.21 
111 120 18.19 ± 1.14 
113 •120 13.01 ± 1.09 
113 -100 12.78 ± 1.07 
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Table A15. (continued) 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 -80 18.30 ± 1.23 
113 -60 17.73 ± 1.07 
113 -55 17.90 ± 1.20 
113 -50 24.03 ± 1.79 
113 -45 18.00 ± 1.73 
113 -40 26.57 ± 2.65 
113 -20 19.70 ± 1.25 
113 0 12.74 ± 0.95 
113 5 11.82 ± 1.03 
113 10 13.18 ± 1.37 
113 15 11.58 ± 1.15 
113 20 14.00 ± 1.27 
113 40 11.22 ± 0.97 
113 60 10.31 ± 0.89 
113 80 14.65 ± 1.34 
113 100 10.28 ± 0.82 
113 120 11.94 ± 1.07 
115 -120 7.98 ± 0.74 
115 -100 8.89 ± 0.87 
115 -80 12.14 ± 1.21 
115 -60 10.04 ± 0.98 
115 -55 9.36 ± 0.87 
115 -50 18.15 ± 1.47 
115 -45 9.79 ± 0.82 
115 -40 11.55 ± 0.88 
115 -20 8.11 ± 0.53 
115 0 8.58 ± 0.79 
115 5 12.92 ± 0.87 
115 10 9.45 ± 0.77 
115 15 7.98 ± 0.87 
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Table A15. (continued) 
Days after Minutes from Prolactin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
115 20 8.07 ± 0.75 
115 40 8.56 ± 0.79 
115 60 8.19 ± 0.58 
115 80 8.59 ± 0.84 
115 100 9.34 ± 0.99 
115 120 . 7.56 ± 0.48 
 ^ICV injections of RU 486 (4mg) were given on days 111,113, 
and 115 after the blood sample collection at time 0 (corresponding to 
1000 h). One hour prior to relaxin injections, all gilts received ICV 
injections of vehicle (100 |il) at time -60 minutes (corresponding to 
0900 h) .  
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Table A16. Relaxin in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricular) injection of RU 
486 (n=5) 
Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 6.87 ± 0.48 
101 6.60 ± 0.82 
102 5.26 ± 0.47 
103 7.17 ± 0.64 
104 7.28 ± 0.87 
105 6.01 ± 0.73 
106 9.41 ± 0.77 
107 10.05 ± 1.01 
108 6.86 ± 0.41 
109 7.17 ± 0.63 
110 4.25 ± , 0.21 
111 -120 5.89 + 0.44 
111 -100 6.09 ± 0.56 
111 -80 6.24 ± 0.62 
111 -60 5.73 ± 0.36 
111 -55 5.29 ± 0.48 
111 -50 5.32 ± 0.41 
111 -45 5.03 ± 0.39 
111 -40 5.42 ± 0.56 
111 -20 5.36 i 0.47 
111 0 5.51 + 0.57 
111 5 5.81 ± 0.53 
111 . 1 0  6.80 ± 0.60 
111 15 8.68 ± 0.77 
111 20 7.55 ± 0.61 
111 40 7.92 ± 0.71 
111 60 6.71 ± 0.42 
111 80 6.75 ± 0.71 
111 100 5.77 ± 0.43 
111 120 5.27 ± 0.36 
113 
113 
-120 
-100 
9.32 
9.83 
± 0.81 
± 0.87 
Table A16. (continued) 
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Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 -80 10.45 + 0.99 
113 -60 6.30 ±  0.53 
113 -55 6.21 ±  0.61 
113 -50 6.01 ±  0.54 
113 -45 6.20 ±  0.49 
113 -40 6.72 ±  0.58 
113 -20 6.24 ±  0.63 
113 0 6.32 ±  0.54 
113 5 6.21 + 0.57 
113 10 6.28 ± 0.69 
113 15 5.99 ±  0.47 
113 20 6.40 ±  0.56 
113 40 6.70 ±  0.59 
113 60 6.51 ±  0.52 
113 80 6.01 ±  0.61 
113 100 6.12 ±  0.66 
113 120 6.86 ±  0.84 
115 -120 16.54 ±  1.01 
115 -100 17.38 ±  1.34 
115 -80 14.30 ±  1.24 
115 -60 17.51 ±  1.29 
115 -55 11.83 ±  •  1.09 
115 -50 13.58 ±  1.01 
115 -45 15.74 ±  1.52 
115 . -40 14.88 ±  1.27 
115 -20 15.53 ± 0.98 
115 0 13.35 ±  1.64 
115 5 14.79 ±  1.47 
115 10 14.50 ± .  1.44 
115 15 12.61 ±  1.00 
Table A16. (continued) 
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Days after Minutes from Relaxin (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
115 20 15.57 ± 1.30 
115 40 15.46 ± 1.07 
115 60 14.26 ± 1.03 
115 80 13.33 ± 1.33 
115 100 13.89 ± 1.01 
115 120 14.87 ± 1.47 
 ^ICV injections of RU 486 (4mg) were given on days 111,113, 
and 115 after the blood sample collection at time 0 (corresponding to 
1000 h). One hour prior to relaxin injections, all gilts received ICV 
injections of vehicle (100 |li1) at time -60 minutes (corresponding to 
0900 h) .  
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Table A17. Progesterone in peripheral plasma of hysterectomized gilts 
received ICV (intracerebroventricular) injection of RU 
486 (n=5) 
Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
100 23.67 ± 1.97 
101 26.49 ± 2.04 
102 26.04 ± 1.06 
103 26.96 + 1..38 
104 22.16 ± 1.32 
105 23.98 ± 2.03 
106 24.25 ± 1.88 
107 24.26 ± 1.64 
108 21.94 ± 1.07 
109 22.76 ± 1.37 
110 15.33 + 0.99 
111 -120 14.86 ± 0.87 
111 -100 15.50 ± 1.02 
111 -80 15.24 + 1.20 
111 -60 14.99 ± 0.87 
111 -55 13.50 ± 1.39 
111 -50 13.33 ± 1.61 
111 -45 12.35 ± 0.93 
111 -40 13.16 + 1.06 
111 -20 16.03 ± 1.36 
111 0 15.12 ± 0.82 
111 5 15.29 ± 1.33 
111 . 10 16.43 ± 1.44 
111 15 16.84 ± 1.28 
111 20 18.10 ± 1.63 
111 40 18.79 ± 1.37 
111 60 17.51 .± 1.39 
111 80 16.57 ± 1.55 
111 100 14.98 ± 0.99 
111 120 14.18 ± 1.20 
113 -120 18.39 ± 1.06 
113 -100 19.93 ± 1.21 
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Table A17. (continued) 
Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
113 -80 18.34 ± 1.35 
113 -60 16.64 ± 1.28 
113 -55 17.81 ± 1.62 
113 -50 15.18 ± 1.27 
113 -45 15.83 ± 1.82 
113 -40 15.53 ± 1.21 
113 -20 16.63 ± 1.64 
113 0 17.81 ± 1.29 
113 5 18.32 ± 1.63 
113 10 20.48 ± 2.04 
113 35 19.31 ± 1.24 
113 20 17.98 ± 1.61 
113 40 19.22 ± 1.87 
113 60 21.66 ± 1.91 
113 80 21.66 ± 1.07 
113 100 20.17 ± 1.34 
113 120 20.39 ± 1.85 
115 -120 14.24 ± 1.07 
115 -100 15.40 ± 1.03 
115 -80 15.21 ± 1.09 
115 -60 15.71 ± 1.01 
115 -55 14.31 ± 1.63 
115 -50 16.32 ± 1.44 
115 •45 16.41 ± 1.23 
115 -40 17.51 ± 1.28 
115 -20 15.81 ± 1.87 
115 0 15.28 ± 1.02 
115 5 13.81 ± 1.03 
115 10 15.10 ± 1.22 
115 15 16.61 ± 1.25 
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Table A17. (continued) 
Days after Minutes from Progesterone (ng/ml, 
estrus ICV injection  ^ mean ± SE) 
115 20 15.80 ± 1.06 
115 40 18.27 ± 1.87 
115 60 22.07 ± 2.38 
115 80 23.74 ± 1.98 
115 100 18.37 ± 1.54 
115 120 20.28 ± 2.07 
 ^ICV injections of RU 486 (4mg) were given on days 111,113, 
and 115 after the blood sample collection at time 0 (corresponding to 
1000 h). One hour prior to relaxin injections, all gilts received ICV 
injections of vehicle (100 jil) at time -60 minutes (corresponding to 
0900 h) .  
